MGH: CoPath coded comments

Code	Output	Subspecialty
Code	Output	Subspecialty
ADH	Atypical ductal hyperplasia	BR
ALH	Lobular neoplasia (atypical lobular hyperplasia)	BR
BDA	Blunt duct adenosis	BR
BRADS	The results of immunohistochemical staining for estrogen receptor, progesterone receptor, and Her2/neu protein expression and of fluorescence in‐situ hybridization studies for Her2/neu gene amplification will be reported in an addendum.	BR
CALC	Calcifications	BR
DCIS	Ductal carcinoma in‐situ	BR
DCIS1	Ductal carcinoma in‐situ, grade 1	BR
DCIS2	Ductal carcinoma in‐situ, grade 2	BR
DCIS3	Ductal carcinoma in‐situ, grade 2	BR
EEEEE	This case does not contain all the coding components for CMS PQRI measure #99.	BR
ERPR	Note: The results of immunohistochemical staining for estrogen and progesterone receptors will be reported in an addendum.	BR
FBA	Fibroadenoma	BR
FCC	Fibrocystic changes	BR
FEA	Flat epithelial atypia	BR
GRDNR	The tumor grade in this limited sample may not be representative of the entire lesion.	BR
HBX	Healing biopsy site	BR
IDC	Invasive ductal carcinoma	BR
ILC	Invasive lobular carcinoma	BR
ITC	Isolated tumor cells	BR
KER1	Immunostained slides for cytokeratin AE1.3/Cam5.2, cytokeratin 7, and cytokeratin MNF116 were examined on tissue levels.	BR
KER2	Immunostained slides for cytokeratin AE1.3/Cam5.2, cytokeratin 7, and cytokeratin MNF116 were examined on tissue levels from each of 2 blocks.	BR
KER3	Immunostained slides for cytokeratin AE1.3/Cam5.2, cytokeratin 7, and cytokeratin MNF116 were examined on tissue levels from each of 3 blocks.	BR
LCIS	Lobular neoplasia (lobular carcinoma in‐situ)	BR
MARG	NOTE: The resection margins of the specimen(s) were inked and microscopically evaluated; see individual gross descriptions.	BR
MARG1	NOTE: The resection margins of the specimen were inked and microscopically evaluated.	BR
MARG2	NOTE: The resection margins of the specimens were inked and microscopically evaluated.	BR
MULTI	The patient’s chart and available radiographs were reviewed at the MGH Breast Center multidisciplinary conference.	BR
PASH	Pseudoangiomatous stromal hyperplasia	BR
RADS	Radial scar	BR
SCA	Sclerosing adenosis	BR
UDH	Usual ductal hyperplasia	BR
BTFX	ACUTE HEMORRHAGE WITH DISRUPTION OF BONY TRABECULAE CONSISTENT WITH RECENT FRACTURE	BST
CPCD	CALCIUM PYROPHOSPHATE CRYSTAL DEPOSITS	BST
DSK1	FRAGMENTS OF DEGENERATED FIBROCARTILAGE (DISC) AND ATTACHED HYALINE CARTILAGE ENDPLATE	BST
DSK2	FRAGMENTS OF DEGENERATED FIBROCARTILAGE (DISC) AND ATTACHED HYALINE CARTILAGE ENDPLATE WITH HISTOLOGIC EVIDENCE OF PROLAPSE	BST
HRN1	FIBROFATTY TISSUE CONSISTENT WITH HERNIA SAC	BST
HRN2	HERNIA SAC	BST
MNSC1	FRAGMENTS OF DEGENERATED FIBROCARTILAGE (MENISCUS)	BST
MNSC2	FRAGMENTS OF DEGENERATED FIBROCARTILAGE (MENISCUS) AND ARTICULAR HYALINE CARTILAGE	BST
MNSC3	FRAGMENTS OF DEGENERATED FIBROCARTILAGE (MENISCUS), ARTICULAR HYALINE CARTILAGE AND PIECES OF SYNOVIUM	BST
OSPHT1	OSTEOARTHRITIS WITH OSTEOPHYTES	BST
OSPHT2	SEVERE OSTEOARTHRITIS WITH EBURNATION, SUBCHONDRAL SCLEROSIS AND CYSTS AND OSTEOPHYTES.	BST
PVNS	PIGMENTED VILLONODULAR SYNOVITIS	BST
SNL1	SYNOVIAL-LIKE TISSUE WITH A PROMINENT MONO AND MULTINUCLEATED HISTIOCYTIC REACTION TO POLYETHYLENE FIBERS AND METAL PARTICLES	BST
SNL2	SYNOVIAL-LIKE TISSUE WITH A PROMINENT MONO AND MULTINUCLEATED HISTIOCYTIC REACTION TO POLYETHYLENE FIBERS, BARIUM IMPREGNATED METHYLMETHACRYLATE AND METAL PARTICLES	BST
THYROSEQ	Genetic testing with ThyroSeq® Genomic Classifier (CBLPath, UPMC, Pittsburgh, PA) is pending. Results will be available in the electronic medical record (EPIC) under the Media tab of Chart Review in approximately two weeks.	CYT
AFIRMA	Genetic testing with Afirma® Genomic Sequencing Classifier (Veracyte™, South San Francisco, CA) is pending.  Results will be available in the electronic medical record (EPIC) under the Media tab of Chart Review in approximately two weeks.	CYT
AFIRMAAD	Afirma testing will be performed, and the results reported in an addendum.	CYT
ORO	"Lipid laden macrophage index of #. Note: An Oil Red O stain is performed for the purposes of calculating a lipid laden macrophage index. A lipid laden index less than 40 is not indicative of aspiration; an index between 40 and 90 is borderline and essentially indeterminate, and an index greater than 90 is suggestive of aspiration."	CYT
OROI	Note: An Oil Red O stain was performed for the purposes of calculating a lipid laden macrophage index, but a lipid laden macrophage index could not be performed due to too few pulmonary macrophages.	CYT
CBTP	There are [ <50 / 50-500 / >500 ] tumor cells present on cell block preparation. Tumor cells comprise [ <15% / 15-50% / >50% ] of the nucleated cells.	CYT
CFL	Note: The lymphoid population appears polymorphous and reactive; however, cytologic interpretation alone may be insensitive to some lymphoproliferative processes due to the overlap in morphological features. To better characterize the lymphoid population, flow cytometry is being performed, the results of which may change this diagnosis. The results will be reported in an addendum and if not supportive of a reactive node, an amended diagnosis will follow.	CYT
FCRC	The lymphoid population appears polymorphous and reactive; however, cytologic interpretation alone may be insensitive to some lymphoproliferative processes due to the overlap in morphological features. If a lymphoproliferative process is of clinical concern, repeat sampling with tissue for flow cytometry warrants clinical consideration.	CYT
SATNEG	Satisfactory, negative…	CYT
SATATY	Satisfactory, atypical…	CYT
SATSUS	Satisfactory, suspicious…	CYT
SATPOS	Satisfactory, positive…	CYT
SATFLUS	Satisfactory, FLUS…	CYT
LIMNEG	Evaluation limited by scant cellularity, negative…	CYT
LIMATY	Evaluation limited by scant cellularity, atypical…	CYT
LIMSUS	Evaluation limited by scant cellularity, suspicious…	CYT
LIMPOS	Evaluation limited by scant cellularity, positive…	CYT
LIMFLUS	Evaluation limited by scant cellularity, FLUS…	CYT
NSCCR	Note: Due to the non-specific nature of the findings, clinical correlation is required to ensure that the sample is representative of the lesion in question.	CYT
ACP	Structures consistent with amoebic cysts are present. Pathogenic and non-pathogenic amoebas cannot be distinguished on cytology, and clinical correlation with additional studies for parasites (e.g., stool examination) may be warranted if clinically indicated.	CYT
AA	ALOPECIA AREATA	DP
AAK	ACANTHOLYTIC ACTINIC KERATOSIS.	DP
AAKPAM	ACANTHOLYTIC ACTINIC KERATOSIS, PRESENT AT MARGIN.	DP
ACI	ACUTE AND CHRONIC INFLAMMATION	DP
ACIU	ACUTE AND CHRONIC INFLAMMATION AND ULCERATION.	DP
ACRO	ACROCHORDON.	DP
AFX	ATYPICAL FIBROXANTHOMA.	DP
AFXPAM	ATYPICAL FIBROXANTHOMA, PRESENT AT MARGIN.	DP
AGEP	ACUTE GENERALIZED EXANTHEMATOUS PUSTULOSIS	DP
AHAKSCC	CONSISTENT WITH ACANTHOLYTIC HYPERTROPHIC ACTINIC KERATOSIS (SEE NOTE). Note: This atypical keratinocytic proliferation extends to the base of the biopsy specimen, invasive squamous cell carcinoma cannot be entirely excluded.	DP
AI	ACUTE INFLAMMATION	DP
AIEC	WITH # CYTOLOGIC ATYPIA OF THE INTRAEPIDERMAL COMPONENT.	DP
AIEDC	WITH # CYTOLOGIC ATYPIA OF THE INTRAEPIDERMAL AND DERMAL COMPONENTS.	DP
AK	ACTINIC KERATOSIS.	DP
AKASCC	CONSISTENT WITH ACTINIC KERATOSIS, ACANTHOLYTIC TYPE (SEE NOTE). Note: This atypical keratinocytic proliferation extends to the base of the biopsy specimen, invasive squamous cell carcinoma cannot be entirely excluded.	DP
AKASCCMLE	CONSISTENT WITH ACTINIC KERATOSIS, ACANTHOLYTIC TYPE, MULTIPLE LEVELS EXAMINED (SEE NOTE). Note: This atypical keratinocytic proliferation extends to the base of the biopsy specimen, invasive squamous cell carcinoma cannot be entirely excluded.	DP
AKCE	ACTINIC KERATOSIS, COMPLETELY EXCISED.	DP
AKPAM	ACTINIC KERATOSIS, PRESENT AT MARGIN.	DP
AKSCC	CONSISTENT WITH ACTINIC KERATOSIS (SEE NOTE). Note: This atypical keratinocytic proliferation extends to the base of the biopsy specimen, invasive squamous cell carcinoma cannot be entirely excluded.	DP
AKSCCMLE	CONSISTENT WITH ACTINIC KERATOSIS, MULTIPLE LEVELS EXAMINED (SEE NOTE). Note: This atypical keratinocytic proliferation extends to the base of the biopsy specimen, invasive squamous cell carcinoma cannot be entirely excluded.	DP
ALSO	This case was also reviewed by Dr. # who agrees with the above diagnosis.	DP
AMP	ATYPICAL MELANOCYTIC PROLIFERATION.	DP
AVH	ARTERIOVENOUS HEMANGIOMA.	DP
BCC	BASAL CELL CARCINOMA	DP
BCCI	BASAL CELL CARCINOMA, INFILTRATIVE TYPE.	DP
BCCICE	BASAL CELL CARCINOMA, INFILTRATIVE TYPE, COMPLETELY EXCISED.	DP
BCCICEMLE	BASAL CELL CARCINOMA, INFILTRATIVE TYPE, COMPLETELY EXCISED, MULTIPLE LEVELS EXAMINED.	DP
BCCIMEMLE	BASAL CELL CARCINOMA, INFILTRATIVE AND METATYPICAL TYPES, MULTIPLE LEVELS EXAMINED.	DP
BCCIPAM	BASAL CELL CARCINOMA, INFILTRATIVE TYPE, PRESENT AT MARGIN.	DP
BCCIPAMMLE	BASAL CELL CARCINOMA, INFILTRATIVE TYPE, PRESENT AT MARGIN, MULTIPLE LEVELS EXAMINED.	DP
BCCM	BASAL CELL CARCINOMA, MICRONODULAR TYPE.	DP
BCCMCE	BASAL CELL CARCINOMA, MICRONODULAR TYPE, COMPLETELY EXCISED.	DP
BCCMCEMLE	BASAL CELL CARCINOMA, MICRONODULAR TYPE, COMPLETELY EXCISED, MULTIPLE LEVELS EXAMINED.	DP
BCCME	BASAL CELL CARCINOMA, METATYPICAL TYPE.	DP
BCCMECE	BASAL CELL CARCINOMA, METATYPICAL TYPE, COMPLETELY EXCISED.	DP
BCCMECEMLE	BASAL CELL CARCINOMA, METATYPICAL TYPE, COMPLETELY EXCISED, MULTIPLE LEVELS EXAMINED.	DP
BCCMEMLE	BASAL CELL CARCINOMA, METATYPICAL TYPE, MULTIPLE LEVELS EXAMINED.	DP
BCCMEPAM	BASAL CELL CARCINOMA, METATYPICAL TYPE, PRESENT AT MARGIN.	DP
BCCMEXNEGBCC	BASAL CELL CARCINOMA, MICRONODULAR TYPE, EXAMINED INKED MARGINS ARE FREE OF BASAL CELL CARCINOMA.	DP
BCCMI	BASAL CELL CARCINOMA, MICRONODULAR AND INFILTRATIVE TYPES.	DP
BCCMIEXNEGBCC	BASAL CELL CARCINOMA, MICRONODULAR AND INFILTRATIVE TYPES. EXAMINED INKED MARGINS ARE FREE OF BASAL CELL CARCINOMA.	DP
BCCMIMLE	BASAL CELL CARCINOMA, MICRONODULAR AND INFILTRATIVE TYPES, MULTIPLE LEVELS EXAMINED.	DP
BCCMIPAMMLE	BASAL CELL CARCINOMA, MICRONODULAR AND INFILTRATIVE TYPES, PRESENT AT MARGIN, MULTIPLE LEVELS EXAMINED.	DP
BCCMLE	BASAL CELL CARCINOMA, MULTIPLE LEVELS EXAMINED.	DP
BCCMMLE	BASAL CELL CARCINOMA, MICRONODULAR TYPE, MULTIPLE LEVELS EXAMINED.	DP
BCCMO	BASAL CELL CARCINOMA, MORPHEA TYPE.	DP
BCCMOCE	BASAL CELL CARCINOMA, MORPHEA TYPE, COMPLETELY EXCISED.	DP
BCCMOME	BASAL CELL CARCINOMA, MORPHEA AND METATYPICAL TYPES.	DP
BCCMOMLE	BASAL CELL CARCINOMA, MORPHEA TYPE, MULTIPLE LEVELS EXAMINED.	DP
BCCMPAM	BASAL CELL CARCINOMA, MICRONODULAR TYPE, PRESENT AT MARGIN.	DP
BCCMPAMMLE	BASAL CELL CARCINOMA, MICRONODULAR TYPE, PRESENT AT MARGIN, MULTIPLE LEVELS EXAMINED.	DP
BCCN	BASAL CELL CARCINOMA, NODULAR TYPE.	DP
BCCNCE	BASAL CELL CARCINOMA, NODULAR TYPE, COMPLETELY EXCISED.	DP
BCCNCEMLE	BASAL CELL CARCINOMA, NODULAR TYPE, COMPLETELY EXCISED, MULTIPLE LEVELS EXAMINED.	DP
BCCNEXNEGBCC	BASAL CELL CARCINOMA, NODULAR TYPE. EXAMINED INKED MARGINS ARE FREE OF BASAL CELL CARCINOMA.	DP
BCCNEXNEGBCCMLE	BASAL CELL CARCINOMA, NODULAR TYPE. EXAMINED INKED MARGINS ARE FREE OF BASAL CELL CARCINOMA, MULTIPLE LEVELS EXAMINED.	DP
BCCNI	BASAL CELL CARCINOMA, NODULAR AND INFILTRATIVE TYPES.	DP
BCCNICE	BASAL CELL CARCINOMA, NODULAR AND INFILTRATIVE TYPES, COMPLETELY EXCISED.	DP
BCCNICEMLE	BASAL CELL CARCINOMA, NODULAR AND INFILTRATIVE TYPES, COMPLETELY EXCISED, MULTIPLE LEVELS EXAMINED.	DP
BCCNIEXNEGBCC	BASAL CELL CARCINOMA, NODULAR AND INFILTRATIVE TYPES. EXAMINED INKED MARGINS ARE FREE OF BASAL CELL CARCINOMA.	DP
BCCNIEXNEGBCCMLE	BASAL CELL CARCINOMA, NODULAR AND INFILTRATIVE TYPES. EXAMINED INKED MARGINS ARE FREE OF BASAL CELL CARCINOMA, MULTIPLE LEVELS EXAMINED.	DP
BCCNIMEMLE	BASAL CELL CARCINOMA, NODULAR, INFILTRATIVE, AND METATYPICAL TYPES, MULTIPLE LEVELS EXAMINED.	DP
BCCNIMLE	BASAL CELL CARCINOMA, NODULAR AND INFILTRATIVE TYPES, MULTIPLE LEVELS EXAMINED.	DP
BCCNIPAM	BASAL CELL CARCINOMA, NODULAR AND INFILTRATIVE TYPES, PRESENT AT MARGIN.	DP
BCCNIPAMMLE	BASAL CELL CARCINOMA, NODULAR AND INFILTRATIVE TYPES, PRESENT AT MARGIN, MULTIPLE LEVELS EXAMINED.	DP
BCCNM	BASAL CELL CARCINOMA, NODULAR AND MICRONODULAR TYPES.	DP
BCCNMCEMLE	BASAL CELL CARCINOMA, NODULAR AND MICRONODULAR TYPES, COMPLETELY EXCISED, MULTIPLE LEVELS EXAMINED.	DP
BCCNME	BASAL CELL CARCINOMA, NODULAR AND METATYPICAL TYPES.	DP
BCCNMEMLE	BASAL CELL CARCINOMA, NODULAR AND METATYPICAL TYPES, MULTIPLE LEVELS EXAMINED.	DP
BCCNMEXNEGBCC	BASAL CELL CARCINOMA, NODULAR AND MICRONODULAR TYPES. EXAMINED INKED MARGINS ARE FREE OF BASAL CELL CARCINOMA.	DP
BCCNMI	BASAL CELL CARCINOMA, NODULAR, MICRONODULAR, AND INFILTRATIVE TYPES.	DP
BCCNMLE	BASAL CELL CARCINOMA, NODULAR TYPE, MULTIPLE LEVELS EXAMINED.	DP
BCCNMMLE	BASAL CELL CARCINOMA, NODULAR AND MICRONODULAR TYPES, MULTIPLE LEVELS EXAMINED.	DP
BCCNMO	BASAL CELL CARCINOMA, NODULAR AND MORPHEA TYPES.	DP
BCCNMPAMMLE	BASAL CELL CARCINOMA, NODULAR AND MICRONODULAR TYPES, PRESENT AT MARGIN, MULTIPLE LEVELS EXAMINED.	DP
BCCS	BASAL CELL CARCINOMA, SUPERFICIAL TYPE.	DP
BCCSCE	BASAL CELL CARCINOMA, SUPERFICIAL TYPE, COMPLETELY EXCISED.	DP
BCCSCEMLE	BASAL CELL CARCINOMA, SUPERFICIAL TYPE, COMPLETELY EXCISED, MULTIPLE LEVELS EXAMINED.	DP
BCCSEXNEGBCC	BASAL CELL CARCINOMA, SUPERFICIAL TYPE. EXAMINED INKED MARGINS ARE FREE OF BASAL CELL CARCINOMA.	DP
BCCSEXNEGBCCMLE	BASAL CELL CARCINOMA, SUPERFICIAL TYPE. EXAMINED INKED MARGINS ARE FREE OF BASAL CELL CARCINOMA, MULTIPLE LEVELS EXAMINED.	DP
BCCSI	BASAL CELL CARCINOMA, SUPERFICIAL AND INFILTRATIVE TYPES.	DP
BCCSICE	BASAL CELL CARCINOMA, SUPERFICIAL AND INFILTRATIVE TYPES, COMPLETELY EXCISED.	DP
BCCSIEXNEGBCC	BASAL CELL CARCINOMA, SUPERFICIAL AND INFILTRATIVE TYPES. EXAMINED INKED MARGINS ARE FREE OF BASAL CELL CARCINOMA.	DP
BCCSIMLE	BASAL CELL CARCINOMA, SUPERFICIAL AND INFILTRATIVE TYPES, MULTIPLE LEVELS EXAMINED.	DP
BCCSIPAM	BASAL CELL CARCINOMA, SUPERFICIAL AND INFILTRATIVE TYPES, PRESENT AT MARGIN.	DP
BCCSIPAMMLE	BASAL CELL CARCINOMA, SUPERFICIAL AND INFILTRATIVE TYPES, PRESENT AT MARGIN, MULTIPLE LEVELS EXAMINED.	DP
BCCSM	BASAL CELL CARCINOMA, SUPERFICIAL AND MICRONODULAR TYPES.	DP
BCCSMCE	BASAL CELL CARCINOMA, SUPERFICIAL AND MICRONODULAR TYPES, COMPLETELY EXCISED.	DP
BCCSME	BASAL CELL CARCINOMA, SUPERFICIAL AND METATYPICAL TYPES.	DP
BCCSMEI	BASAL CELL CARCINOMA, SUPERFICIAL, METATYPICAL, AND INFILTRATIVE TYPES.	DP
BCCSMEMLE	BASAL CELL CARCINOMA, SUPERFICIAL AND METATYPICAL TYPES, MULTIPLE LEVELS EXAMINED.	DP
BCCSMI	BASAL CELL CARCINOMA, SUPERFICIAL, MICRONODULAR, AND INFILTRATIVE TYPES.	DP
BCCSMIMLE	BASAL CELL CARCINOMA, SUPERFICIAL, MICRONODULAR AND INFILTRATIVE TYPES, MULTIPLE LEVELS EXAMINED.	DP
BCCSMLE	BASAL CELL CARCINOMA, SUPERFICIAL TYPE, MULTIPLE LEVELS EXAMINED.	DP
BCCSMMLE	BASAL CELL CARCINOMA, SUPERFICIAL AND MICRONODULAR TYPES, MULTIPLE LEVELS EXAMINED.	DP
BCCSMPAMMLE	BASAL CELL CARCINOMA, SUPERFICIAL AND MICRONODULAR TYPES, PRESENT AT MARGIN, MULTIPLE LEVELS EXAMINED.	DP
BCCSN	BASAL CELL CARCINOMA, SUPERFICIAL AND NODULAR TYPES.	DP
BCCSNCE	BASAL CELL CARCINOMA, SUPERFICIAL AND NODULAR TYPES, COMPLETELY EXCISED.	DP
BCCSNCEMLE	BASAL CELL CARCINOMA, SUPERFICIAL AND NODULAR TYPES, COMPLETELY EXCISED, MULTIPLE LEVELS EXAMINED.	DP
BCCSNEXNEGBCC	BASAL CELL CARCINOMA, SUPERFICIAL AND NODULAR TYPES. EXAMINED INKED MARGINS ARE FREE OF BASAL CELL CARCINOMA.	DP
BCCSNEXNEGBCCMLE	BASAL CELL CARCINOMA, SUPERFICIAL AND NODULAR TYPES. EXAMINED INKED MARGINS ARE FREE OF BASAL CELL CARCINOMA, MULTIPLE LEVELS EXAMINED.	DP
BCCSNI	BASAL CELL CARCINOMA, SUPERFICIAL, NODULAR, AND INFILTRATIVE TYPES.	DP
BCCSNICE	BASAL CELL CARCINOMA, SUPERFICIAL, NODULAR, AND INFILTRATIVE TYPES, COMPLETELY EXCISED.	DP
BCCSNICEMLE	BASAL CELL CARCINOMA, SUPERFICIAL, NODULAR, AND INFILTRATIVE TYPES, COMPLETELY EXCISED, MULTIPLE LEVELS EXAMINED.	DP
BCCSNIEXNEGBCCMLE	BASAL CELL CARCINOMA, SUPERFICIAL, NODULAR, AND INFILTRATIVE TYPES. EXAMINED INKED MARGINS ARE FREE OF BASAL CELL CARCINOMA, MULTIPLE LEVELS EXAMINED.	DP
BCCSNIME	BASAL CELL CARCINOMA, SUPERFICIAL, NODULAR, INFILTRATIVE AND METATYPICAL TYPES.	DP
BCCSNIMLE	BASAL CELL CARCINOMA, SUPERFICIAL, NODULAR, AND INFILTRATIVE TYPES, MULTIPLE LEVELS EXAMINED.	DP
BCCSNIPAM	BASAL CELL CARCINOMA, SUPERFICIAL, NODULAR, AND INFILTRATIVE TYPES, PRESENT AT MARGIN.	DP
BCCSNIPAMMLE	BASAL CELL CARCINOMA, SUPERFICIAL, NODULAR, AND INFILTRATIVE TYPES, PRESENT AT MARGIN, MULTIPLE LEVELS EXAMINED.	DP
BCCSNM	BASAL CELL CARCINOMA, SUPERFICIAL, NODULAR AND MICRONODULAR TYPES.	DP
BCCSNMLE	BASAL CELL CARCINOMA, SUPERFICIAL AND NODULAR TYPES, MULTIPLE LEVELS EXAMINED.	DP
BCCSNPAM	BASAL CELL CARCINOMA, SUPERFICIAL AND NODULAR TYPES, PRESENT AT MARGIN.	DP
BCCSNPAMMLE	BASAL CELL CARCINOMA, SUPERFICIAL AND NODULAR TYPES, PRESENT AT MARGIN, MULTIPLE LEVELS EXAMINED.	DP
BCCSPAMMLE	BASAL CELL CARCINOMA, SUPERFICIAL TYPE, PRESENT AT MARGIN, MULTIPLE LEVELS EXAMINED.	DP
BN	BLUE NEVUS.	DP
BNCEMLE	BLUE NEVUS, COMPLETELY EXCISED, MULTIPLE LEVELS EXAMINED.	DP
BNPAM	BLUE NEVUS, PRESENT AT MARGIN.	DP
BNPAMMLE	BLUE NEVUS, PRESENT AT MARGIN, MULTIPLE LEVELS EXAMINED.	DP
BP	bullous pemphigoid.	DP
BPEH	BENIGN PAPILLARY EPIDERMAL HYPERPLASIA	DP
BXO	BALANITIS XEROTICA OBLITERANS.	DP
CBEE	cannot be entirely excluded.	DP
CCA	CLEAR CELL ACANTHOMA.	DP
CCAMLE	CLEAR CELL ACANTHOMA, MULTIPLE LEVELS EXAMINED.	DP
CCIR	Clinical correlation is recommended.	DP
CCN	CONGENITAL COMPOUND NEVUS.	DP
CCNCE	CONGENITAL COMPOUND NEVUS, COMPLETELY EXCISED.	DP
CCNMLE	CONGENITAL COMPOUND NEVUS, MULTIPLE LEVELS EXAMINED.	DP
CCNPAM	CONGENITAL COMPOUND NEVUS, PRESENT AT MARGIN.	DP
CCNPAMMLE	CONGENITAL COMPOUND NEVUS, PRESENT AT MARGIN, MULTIPLE LEVELS EXAMINED.	DP
CDN	CONGENITAL DERMAL NEVUS.	DP
CDNAIEC	CONGENITAL DERMAL NEVUS WITH # CYTOLOGIC ATYPIA OF THE INTRAEPIDERMAL COMPONENT.	DP
CDNAIECCE	CONGENITAL DERMAL NEVUS WITH # CYTOLOGIC ATYPIA OF THE INTRAEPIDERMAL COMPONENT, COMPLETELY EXCISED.	DP
CDNAIECCEMLE	CONGENITAL DERMAL NEVUS WITH # CYTOLOGIC ATYPIA OF THE INTRAEPIDERMAL COMPONENT, COMPLETELY EXCISED, MULTIPLE LEVELS EXAMINED.	DP
CDNAIECMLE	CONGENITAL DERMAL NEVUS WITH # CYTOLOGIC ATYPIA OF THE INTRAEPIDERMAL COMPONENT, MULTIPLE LEVELS EXAMINED.	DP
CDNAIECPAM	CONGENITAL DERMAL NEVUS WITH # CYTOLOGIC ATYPIA OF THE INTRAEPIDERMAL COMPONENT, PRESENT AT MARGIN.	DP
CDNMLE	CONGENITAL DERMAL NEVUS, MULTIPLE LEVELS EXAMINED.	DP
CDNPAM	CONGENITAL DERMAL NEVUS, PRESENT AT MARGIN.	DP
CDNPAMMLE	CONGENITAL DERMAL NEVUS, PRESENT AT MARGIN, MULTIPLE LEVELS EXAMINED.	DP
CEMLE	COMPLETELY EXCISED, MULTIPLE LEVELS EXAMINED.	DP
CESNN	COMPLETELY EXCISED (SEE NOTE). Note:	DP
CLIN	The clinician has been notified by page/e-mail of the findings on #.	DP
CN	COMPOUND NEVUS.	DP
CNCE	COMPOUND NEVUS, COMPLETELY EXCISED.	DP
CNCEMLE	COMPOUND NEVUS, COMPLETELY EXCISED, MULTIPLE LEVELS EXAMINED.	DP
CNFOC	COMPOUND NEVUS WITH FEATURES OF CONGENITAL ONSET.	DP
CNFOCCEMLE	COMPOUND NEVUS WITH FEATURES OF CONGENITAL ONSET, COMPLETELY EXCISED, MULTIPLE LEVELS EXAMINED.	DP
CNFOCMLE	COMPOUND NEVUS WITH FEATURES OF CONGENITAL ONSET, MULTIPLE LEVELS EXAMINED.	DP
CNFOCPAM	COMPOUND NEVUS WITH FEATURES OF CONGENITAL ONSET, PRESENT AT MARGIN.	DP
CNH	CHONDRODERMATITIS NODULARIS HELICIS.	DP
CNHMLE	CHONDRODERMATITIS NODULARIS HELICIS, MULTIPLE LEVELS EXAMINED.	DP
CNMLE	COMPOUND NEVUS, MULTIPLE LEVELS EXAMINED.	DP
CNN	COMPOUND NEVUS, NEUROTIZED.	DP
CNNMLE	COMPOUND NEVUS, NEUROTIZED, MULTIPLE LEVELS EXAMINED.	DP
CNNPAM	COMPOUND NEVUS, NEUROTIZED, PRESENT AT MARGIN.	DP
CNPAM	COMPOUND NEVUS, PRESENT AT MARGIN.	DP
CNPAMMLE	COMPOUND NEVUS, PRESENT AT MARGIN, MULTIPLE LEVELS EXAMINED.	DP
COND	condyloma acuminatum.	DP
CONDMLE	CONDYLOMA ACUMINATUM, MULTIPLE LEVELS EXAMINED.	DP
CONS	This case has been reviewed by Drs. Lyn M. Duncan, Mai P. Hoang, Rosalynn M. Nazarian, Martin C. Mihm, Adriano Piris, and Stefan Kraft at the Dermatopathology Consensus Conference on # and all are in agreement with the above interpretation.	DP
CPC	Clinicopathologic correlation is recommended.	DP
CTCL	cutaneous T-cell lymphoma	DP
CTD	connective tissue disease	DP
CWAA	CONSISTENT WITH ALOPECIA AREATA.	DP
CWAK	CONSISTENT WITH ACTINIC KERATOSIS.	DP
CWAKMLE	CONSISTENT WITH ACTINIC KERATOSIS, MULTIPLE LEVELS EXAMINED.	DP
CWEIC	CONSISTENT WITH EPIDERMAL INCLUSION CYST.	DP
CWEICR	CONSISTENT WITH RUPTURED EPIDERMAL INCLUSION CYST.	DP
DDX	The differential diagnosis includes	DP
DEJ	DERMO-EPIDERMAL JUNCTION	DP
DF	DERMATOFIBROMA.	DP
DFCEMLE	DERMATOFIBROMA, COMPLETELY EXCISED, MULTIPLE LEVELS EXAMINED.	DP
DFMLE	DERMATOFIBROMA, MULTIPLE LEVELS EXAMINED.	DP
DFPAM	DERMATOFIBROMA, PRESENT AT MARGIN.	DP
DFSP	DERMATOFIBROSARCOMA PROTUBERANS.	DP
DH	DERMATITIS HERPETIFORMIS.	DP
DIC	DISSEMINATED INTRAVASCULAR COAGULATION.	DP
DIF	direct immunofluorescence	DP
DIFGROSS	Received in Zeuss fixative is a punch biopsy of skin. It is washed with buffered saline and frozen entirely.	DP
DLE	DISCOID LUPUS ERYTHEMATOSUS.	DP
DM	DERMATOMYOSITIS	DP
DN	DERMAL NEVUS	DP
DNCE	DERMAL NEVUS, COMPLETELY EXCISED.	DP
DNCEMLE	DERMAL NEVUS, COMPLETELY EXCISED, MULTIPLE LEVELS EXAMINED.	DP
DNEXNEG	DERMAL NEVUS. THE EXAMINED INKED MARGINS ARE FREE.	DP
DNFOC	DERMAL NEVUS WITH FEATURES OF CONGENITAL ONSET.	DP
DNFOCMLE	DERMAL NEVUS WITH FEATURES OF CONGENITAL ONSET, MULTIPLE LEVELS EXAMINED.	DP
DNFOCPAM	DERMAL NEVUS WITH FEATURES OF CONGENITAL ONSET, PRESENT AT MARGIN.	DP
DNMLE	DERMAL NEVUS, MULTIPLE LEVELS EXAMINED.	DP
DNN	DERMAL NEVUS, NEUROTIZED.	DP
DNNFOC	DERMAL NEVUS, NEUROTIZED, WITH FEATURES OF CONGENITAL ONSET.	DP
DNNFOCMLE	DERMAL NEVUS, NEUROTIZED, WITH FEATURES OF CONGENITAL ONSET, MULTIPLE LEVELS EXAMINED.	DP
DNNMLE	DERMAL NEVUS, NEUROTIZED, MULTIPLE LEVELS EXAMINED.	DP
DNPAM	DERMAL NEVUS, PRESENT AT MARGIN.	DP
DSAP	DISSEMINATED SUPERFICIAL ACTINIC POROKERATOSIS.	DP
DSAPMLE	DISSEMINATED SUPERFICIAL ACTINIC POROKERATOSIS, MULTIPLE LEVELS EXAMINED.	DP
DYSN	DYSPLASTIC NEVUS	DP
EAC	ERYTHEMA ANNULARE CENTRIFUGUM.	DP
EACMLE	ERYTHEMA ANNULARE CENTRIFUGUM, MULTIPLE LEVELS EXAMINED.	DP
EBA	EPIDERMOLYSIS BULLOSA ACQUISITA.	DP
ECZD	eczematous dermatitis.	DP
EIC	EPIDERMAL INCLUSION CYST	DP
EICR	EPIDERMAL INCLUSION CYST, RUPTURED.	DP
EICRMLE	EPIDERMAL INCLUSION CYST, RUPTURED, MULTIPLE LEVELS EXAMINED.	DP
EM	erythema multiforme.	DP
EMPD	EXTRAMAMMARY PAGET'S DISEASE	DP
ENSURE	Clinical correlation is recommended to help insure the biopsy is representative of the underlying lesion.	DP
ETDM	EXTENDING TO THE DEEP MARGIN	DP
ETLM	EXTENDING TO THE LATERAL MARGIN	DP
ETLMMLE	EXTENDING TO THE LATERAL MARGIN, MULTIPLE LEVELS EXAMINED.	DP
ETM	EXTENDING TO THE MARGIN.	DP
ETTE	EXTENDING TO THE TISSUE EDGES	DP
ETTEMLE	EXTENDING TO THE TISSUE EDGES, MULTIPLE LEVELS EXAMINED.	DP
ETWM	EXTENDS TO WITHIN # MM OF THE # MARGIN.	DP
EXNEG	THE EXAMINED INKED MARGINS ARE FREE.	DP
EXNEGBCC	EXAMINED INKED MARGINS ARE FREE OF BASAL CELL CARCINOMA.	DP
EXNEGMLE	THE EXAMINED INKED MARGINS ARE FREE, MULTIPLE LEVELS EXAMINED.	DP
EXNEGMM	EXAMINED INKED MARGINS ARE FREE OF MALIGNANT MELANOMA.	DP
EXNEGMMIS	THE EXAMINED INKED MARGINS ARE FREE OF MALIGNANT MELANOMA IN SITU.	DP
EXNEGNEV	EXAMINED INKED MARGINS ARE FREE OF ATYPICAL NEVOMELANOCYTES.	DP
EXNEGSCC	EXAMINED INKED MARGINS ARE FREE OF SQUAMOUS CELL CARCINOMA.	DP
FAD	FOCAL ACANTHOLYTIC DYSKERATOSIS	DP
FADMLE	FOCAL ACANTHOLYTIC DYSKERATOSIS, MULTIPLE LEVELS EXAMINED.	DP
FCW	The findings are consistent with	DP
FDE	FIXED DRUG ERUPTION	DP
FEVDX	may be helpful in further evaluation and diagnosis.	DP
FFPE	formalin-fixed, paraffin-embedded tissue	DP
FIC	FOLLICULOINFUNDIBULAR CYST.	DP
FICMLE	FOLLICULOINFUNDIBULAR CYST, MULTIPLE LEVELS EXAMINED.	DP
FIP	FIBROUS PAPULE.	DP
FIPMLE	FIBROUS PAPULE, MULTIPLE LEVELS EXAMINED.	DP
FOC	WITH FEATURES OF CONGENITAL ONSET	DP
FOCCEMLE	WITH FEATURES OF CONGENITAL ONSET, COMPLETELY EXCISED, MULTIPLE LEVELS EXAMINED.	DP
FOCPAM	WITH FEATURES OF CONGENITAL ONSET, PRESENT AT MARGINS.	DP
FOCPAMMLE	WITH FEATURES OF CONGENITAL ONSET, PRESENT AT MARGINS, MULTIPLE LEVELS EXAMINED.	DP
FRO	FRAGMENTS OF	DP
GAMLE	GRANULOMA ANNULARE, MULTIPLE LEVELS EXAMINED.	DP
GRAD	GRANULOMATOUS DERMATITIS.	DP
GVHD	GRAFT-VERSUS-HOST DISEASE.	DP
HAK	HYPERTROPHIC ACTINIC KERATOSIS.	DP
HAKMLE	HYPERTROPHIC ACTINIC KERATOSIS, MULTIPLE LEVELS EXAMINED.	DP
HAKPAM	HYPERTROPHIC ACTINIC KERATOSIS, PRESENT AT MARGIN.	DP
HAKSCC	CONSISTENT WITH HYPERTROPHIC ACTINIC KERATOSIS (SEE NOTE). Note: This atypical keratinocytic proliferation extends to the base of the biopsy specimen, invasive squamous cell carcinoma cannot be entirely excluded.	DP
HAKSCCMLE	CONSISTENT WITH HYPERTROPHIC ACTINIC KERATOSIS, MULTIPLE LEVELS EXAMINED (SEE NOTE). Note: This atypical keratinocytic proliferation extends to the base of the biopsy specimen, invasive squamous cell carcinoma cannot be entirely excluded.	DP
HAKSCCPAMMLE	CONSISTENT WITH HYPERTROPHIC ACTINIC KERATOSIS, PRESENT AT MARGIN, MULTIPLE LEVELS EXAMINED (SEE NOTE). Note: This atypical keratinocytic proliferation extends to the base of the biopsy specimen, invasive squamous cell carcinoma cannot be entirely excluded.	DP
HIDS	HIDRADENITIS SUPPURATIVA.	DP
HK	HYPERKERATOSIS	DP
HLP	HYPERTROPHIC LICHEN PLANUS.	DP
HM	HEMANGIOMA.	DP
HMLE	HEMANGIOMA, MULTIPLE LEVELS EXAMINED.	DP
HPV	HUMAN PAPILLOMAVIRUS.	DP
HRX	hypersensitivity reaction.	DP
HRXA	hypersensitivity reaction, as to arthropod bite or infestation.	DP
HRXC	hypersensitivity reaction, as to contactant.	DP
HRXD	hypersensitivity reaction, such as to drug.	DP
HRXDA	a hypersensitivity reaction, such as to drug or arthropod bite or infestation.	DP
HRXDC	hypersensitivity reaction, such as to drug or contactant.	DP
HRXDCA	hypersensitivity reaction, such as to drug, contactant, or arthropod bite or infestation.	DP
IFK	INVERTED FOLLICULAR KERATOSIS.	DP
IFKMLE	INVERTED FOLLICULAR KERATOSIS, MULTIPLE LEVELS EXAMINED.	DP
IHCREV	Immunohistochemical studies performed at the referring laboratory and reviewed at Massachusetts General Hospital reveal	DP
ILVEN	INFLAMMATORY LINEAR VERRUCOUS EPIDERMAL NEVUS	DP
INTD	INTERFACE DERMATITIS	DP
ITAN	INVERTED TYPE-A NEVUS.	DP
ITANMLE	INVERTED TYPE-A NEVUS, MULTIPLE LEVELS EXAMINED.	DP
JN	JUNCTIONAL NEVUS.	DP
JNCEMLE	JUNCTIONAL NEVUS, COMPLETELY EXCISED, MULTIPLE LEVELS EXAMINED.	DP
JNMLE	JUNCTIONAL NEVUS, MULTIPLE LEVELS EXAMINED.	DP
JNPAM	JUNCTIONAL NEVUS, PRESENT AT MARGIN.	DP
JXG	JUVENILE XANTHOGRANULOMA.	DP
KA	KERATOACANTHOMA.	DP
KS	KAPOSI'S SARCOMA	DP
KSMLE	KAPOSI'S SARCOMA, MULTIPLE LEVELS EXAMINED.	DP
LAK	LICHENOID ACTINIC KERATOSIS.	DP
LAKCE	LICHENOID ACTINIC KERATOSIS, COMPLETELY EXCISED.	DP
LAKMLE	LICHENOID ACTINIC KERATOSIS, MULTIPLE LEVELS EXAMINED.	DP
LAKSCC	CONSISTENT WITH LICHENOID ACTINIC KERATOSIS (SEE NOTE). Note: This atypical keratinocytic proliferation extends to the base of the biopsy specimen, invasive squamous cell carcinoma cannot be entirely excluded.	DP
LCDNAIEC	LENTIGINOUS COMPOUND DYSPLASTIC NEVUS WITH # CYTOLOGIC ATYPIA OF THE INTRAEPIDERMAL COMPONENT.	DP
LCDNAIECCE	LENTIGINOUS COMPOUND DYSPLASTIC NEVUS WITH # CYTOLOGIC ATYPIA OF THE INTRAEPIDERMAL COMPONENT, COMPLETELY EXCISED.	DP
LCDNAIECCEMLE	LENTIGINOUS COMPOUND DYSPLASTIC NEVUS WITH # CYTOLOGIC ATYPIA OF THE INTRAEPIDERMAL COMPONENT, COMPLETELY EXCISED, MULTIPLE LEVELS EXAMINED.	DP
LCDNAIECPAM	LENTIGINOUS COMPOUND DYSPLASTIC NEVUS WITH # CYTOLOGIC ATYPIA OF THE INTRAEPIDERMAL COMPONENT, PRESENT AT MARGIN.	DP
LCDNAIECPAMMLE	LENTIGINOUS COMPOUND DYSPLASTIC NEVUS WITH # CYTOLOGIC ATYPIA OF THE INTRAEPIDERMAL COMPONENT, PRESENT AT MARGIN, MULTIPLE LEVELS EXAMINED.	DP
LCDNAIEDC	LENTIGINOUS COMPOUND DYSPLASTIC NEVUS WITH # CYTOLOGIC ATYPIA OF THE INTRAEPIDERMAL AND DERMAL COMPONENTS.	DP
LCDNAIEDCCE	LENTIGINOUS COMPOUND DYSPLASTIC NEVUS WITH # CYTOLOGIC ATYPIA OF THE INTRAEPIDERMAL AND DERMAL COMPONENTS, COMPLETELY EXCISED.	DP
LCDNAIEDCCEMLE	LENTIGINOUS COMPOUND DYSPLASTIC NEVUS WITH # CYTOLOGIC ATYPIA OF THE INTRAEPIDERMAL AND DERMAL COMPONENTS, COMPLETELY EXCISED, MULTIPLE LEVELS EXAMINED.	DP
LCDNAIEDCMLE	LENTIGINOUS COMPOUND DYSPLASTIC NEVUS WITH # CYTOLOGIC ATYPIA OF THE INTRAEPIDERMAL AND DERMAL COMPONENTS, MULTIPLE LEVELS EXAMINED.	DP
LCDNAIEDCPAM	LENTIGINOUS COMPOUND DYSPLASTIC NEVUS WITH # CYTOLOGIC ATYPIA OF THE INTRAEPIDERMAL AND DERMAL COMPONENTS, PRESENT AT MARGIN.	DP
LCDNAIEDCPAMMLE	LENTIGINOUS COMPOUND DYSPLASTIC NEVUS WITH # CYTOLOGIC ATYPIA OF THE INTRAEPIDERMAL AND DERMAL COMPONENTS, PRESENT AT MARGINS, MULTIPLE LEVELS EXAMINED.	DP
LCDNCE	LENTIGINOUS COMPOUND DYSPLASTIC NEVUS WITH # CYTOLOGIC ATYPIA, COMPLETELY EXCISED.	DP
LCDNCEMLE	LENTIGINOUS COMPOUND DYSPLASTIC NEVUS WITH # CYTOLOGIC ATYPIA, COMPLETELY EXCISED, MULTIPLE LEVELS EXAMINED.	DP
LCDNMLE	LENTIGINOUS COMPOUND DYSPLASTIC NEVUS WITH # CYTOLOGIC ATYPIA, MULTIPLE LEVELS EXAMINED.	DP
LCDNPAM	LENTIGINOUS COMPOUND DYSPLASTIC NEVUS WITH # CYTOLOGIC ATYPIA, PRESENT AT MARGIN.	DP
LCDNPAMMLE	LENTIGINOUS COMPOUND DYSPLASTIC NEVUS WITH # CYTOLOGIC ATYPIA, PRESENT AT MARGIN, MULTIPLE LEVELS EXAMINED.	DP
LCH	LOBULAR CAPILLARY HEMANGIOMA (PYOGENIC GRANULOMA).	DP
LCHMLE	LOBULAR CAPILLARY HEMANGIOMA (PYOGENIC GRANULOMA), MULTIPLE LEVELS EXAMINED.	DP
LCN	LENTIGINOUS COMPOUND NEVUS.	DP
LCNAIEC	LENTIGINOUS COMPOUND NEVUS WITH # CYTOLOGIC ATYPIA OF THE INTRAEPIDERMAL COMPONENT.	DP
LCNAIECCE	LENTIGINOUS COMPOUND NEVUS WITH # CYTOLOGIC ATYPIA OF THE INTRAEPIDERMAL COMPONENT, COMPLETELY EXCISED.	DP
LCNAIECCEMLE	LENTIGINOUS COMPOUND NEVUS WITH # CYTOLOGIC ATYPIA OF THE INTRAEPIDERMAL COMPONENT, COMPLETELY EXCISED, MULTIPLE LEVELS EXAMINED.	DP
LCNAIECEXNEGMLE	LENTIGINOUS COMPOUND NEVUS WITH # CYTOLOGIC ATYPIA OF THE INTRAEPIDERMAL COMPONENT. EXAMINED INKED MARGINS ARE FREE, MULTIPLE LEVELS EXAMINED.	DP
LCNAIECPAM	LENTIGINOUS COMPOUND NEVUS WITH # CYTOLOGIC ATYPIA OF THE INTRAEPIDERMAL COMPONENT, PRESENT AT MARGIN.	DP
LCNAIECPAMMLE	LENTIGINOUS COMPOUND NEVUS WITH # CYTOLOGIC ATYPIA OF THE INTRAEPIDERMAL COMPONENT, PRESENT AT MARGIN, MULTIPLE LEVELS EXAMINED.	DP
LCNAIEDC	LENTIGINOUS COMPOUND NEVUS WITH # CYTOLOGIC ATYPIA OF THE INTRAEPIDERMAL AND DERMAL COMPONENTS.	DP
LCNCE	LENTIGINOUS COMPOUND NEVUS WITH # CYTOLOGICAL ATYPIA, COMPLETELY EXCISED.	DP
LCNCEMLE	LENTIGINOUS COMPOUND NEVUS, COMPLETELY EXCISED, MULTIPLE LEVELS EXAMINED.	DP
LCNEXNEGMLE	LENTIGINOUS COMPOUND NEVUS WITH # CYTOLOGIC ATYPIA, EXAMINED INKED MARGINS ARE FREE, MULTIPLE LEVELS EXAMINED.	DP
LCNFOC	LENTIGINOUS COMPOUND NEVUS WITH FEATURES OF CONGENITAL ONSET.	DP
LCNFOCCE	LENTIGINOUS COMPOUND NEVUS WITH FEATURES OF CONGENITAL ONSET, COMPLETELY EXCISED.	DP
LCNFOCCEMLE	LENTIGINOUS COMPOUND NEVUS WITH FEATURES OF CONGENITAL ONSET, COMPLETELY EXCISED, MULTIPLE LEVELS EXAMINED.	DP
LCNFOCMLE	LENTIGINOUS COMPOUND NEVUS WITH FEATURES OF CONGENITAL ONSET, MULTIPLE LEVELS EXAMINED.	DP
LCNFOCPAM	LENTIGINOUS COMPOUND NEVUS WITH FEATURES OF CONGENITAL ONSET, PRESENT AT MARGIN.	DP
LCNFOCPAMMLE	LENTIGINOUS COMPOUND NEVUS WITH FEATURES OF CONGENITAL ONSET, PRESENT AT MARGINS, MULTIPLE LEVELS EXAMINED.	DP
LCNMLE	LENTIGINOUS COMPOUND NEVUS, MULTIPLE LEVELS EXAMINED.	DP
LCNPAM	LENTIGINOUS COMPOUND NEVUS, PRESENT AT MARGIN.	DP
LCV	LEUKOCYTOCLASTIC VASCULITIS.	DP
LCVMLE	LEUKOCYTOCLASTIC VASCULITIS, MULTIPLE LEVELS EXAMINED.	DP
LHAK	LICHENOID HYPERTROPHIC ACTINIC KERATOSIS.	DP
LHAKMLE	LICHENOID HYPERTROPHIC ACTINIC KERATOSIS, MULTIPLE LEVELS EXAMINED.	DP
LHAKSCC	CONSISTENT WITH LICHENOID HYPERTROPHIC ACTINIC KERATOSIS (SEE NOTE). Note: This atypical keratinocytic proliferation extends to the base of the biopsy specimen, invasive squamous cell carcinoma cannot be entirely excluded.	DP
LJDN	LENTIGINOUS JUNCTIONAL DYSPLASTIC NEVUS WITH # CYTOLOGIC ATYPIA.	DP
LJDNCEMLE	LENTIGINOUS JUNCTIONAL DYSPLASTIC NEVUS WITH # CYTOLOGIC ATYPIA, COMPLETELY EXCISED, MULTIPLE LEVELS EXAMINED.	DP
LJDNMLE	LENTIGINOUS JUNCTIONAL DYSPLASTIC NEVUS WITH # CYTOLOGIC ATYPIA, MULTIPLE LEVELS EXAMINED.	DP
LJDNPAM	LENTIGINOUS JUNCTIONAL DYSPLASTIC NEVUS WITH # CYTOLOGIC ATYPIA, PRESENT AT MARGIN.	DP
LJN	LENTIGINOUS JUNCTIONAL NEVUS.	DP
LJNCE	LENTIGINOUS JUNCTIONAL NEVUS WITH # CYTOLOGIC ATYPIA, COMPLETELY EXCISED.	DP
LJNCEMLE	LENTIGINOUS JUNCTIONAL NEVUS, COMPLETELY EXCISED, MULTIPLE LEVELS EXAMINED.	DP
LJNEXNEGMLE	LENTIGINOUS JUNCTIONAL NEVUS WITH # CYTOLOGIC ATYPIA, EXAMINED INKED MARGINS ARE FREE, MULTIPLE LEVELS EXAMINED.	DP
LJNMLE	LENTIGINOUS JUNCTIONAL NEVUS, MULTIPLE LEVELS EXAMINED.	DP
LJNPAM	LENTIGINOUS JUNCTIONAL NEVUS WITH # CYTOLOGIC ATYPIA, PRESENT AT MARGIN.	DP
LJNPAMMLE	LENTIGINOUS JUNCTIONAL NEVUS, PRESENT AT MARGINS, MULTIPLE LEVELS EXAMINED.	DP
LK	LICHENOID KERATOSIS.	DP
LKMLE	LICHENOID KERATOSIS, MULTIPLE LEVELS EXAMINED.	DP
LM	LENTIGO MALIGNA.	DP
LMH	LENTIGINOUS MELANOCYTIC HYPERPLASIA.	DP
LMLE	LENTIGO, MULTIPLE LEVELS EXAMINED.	DP
LMMIS	LENTIGO MALIGNA MELANOMA IN SITU.	DP
LMMLE	LENTIGO MALIGNA, MULTIPLE LEVELS EXAMINED.	DP
LMS	LEIOMYOSARCOMA.	DP
LNB	LYMPH NODE (), BIOPSY:	DP
LND	LYMPH NODES (), DISSECTION:	DP
LNE	LYMPH NODE (), EXCISION:	DP
LNEB	LYMPH NODE (), EXCISIONAL BIOPSY:	DP
LP	LICHEN PLANUS.	DP
LPD	LYMPHOPROLIFERATIVE DISORDER.	DP
LPLK	LICHEN-PLANUS-LIKE KERATOSIS (SEE NOTE). Note: The differential diagnosis includes lichen planus pigmentosa, and, less likely, a fixed drug eruption.	DP
LPMLE	LICHEN PLANUS, MULTIPLE LEVELS EXAMINED.	DP
LPP	LICHEN PLANOPILARIS.	DP
LPPMLE	LICHEN PLANOPILARIS, MULTIPLE LEVELS EXAMINED.	DP
LSA	LICHEN SCLEROSUS.	DP
LSAMLE	LICHEN SCLEROSUS, MULTIPLE LEVELS EXAMINED.	DP
LSC	LICHEN SIMPLEX CHRONICUS.	DP
LSCMLE	LICHEN SIMPLEX CHRONICUS, MULTIPLE LEVELS EXAMINED.	DP
LVI	LYMPHOVASCULAR INVASION	DP
MANIAC	MELANOCYTIC ACRAL NEVUS WITH INTRAEPIDERMAL ASCENT OF CELLS.	DP
MEAS	MEASUREMENT TO CLOSEST SIDE RESECTION MARGIN, # MM	DP
MELH	melanocytic hyperplasia	DP
MF	MYCOSIS FUNGOIDES	DP
MFMLE	MYCOSIS FUNGOIDES, MULTIPLE LEVELS EXAMINED.	DP
MMIS	MALIGNANT MELANOMA IN SITU.	DP
MMISCE	MALIGNANT MELANOMA IN SITU, COMPLETELY EXCISED.	DP
MMISCEMLE	MALIGNANT MELANOMA IN SITU, COMPLETELY EXCISED, MULTIPLE LEVELS EXAMINED.	DP
MMISMLE	MALIGNANT MELANOMA IN SITU, MULTIPLE LEVELS EXAMINED.	DP
MMISPAM	MALIGNANT MELANOMA IN SITU, PRESENT AT MARGIN.	DP
MMM	METASTATIC MALIGNANT MELANOMA.	DP
MMMPAM	METASTATIC MALIGNANT MELANOMA, PRESENT AT MARGIN.	DP
MMRGP	MALIGNANT MELANOMA TYPE: # ANATOMIC LEVEL: # GREATEST THICKNESS: # MM MITOSES: # PER SQUARE MM ULCERATION: ABSENT RADIAL GROWTH PHASE: PRESENT VERTICAL GROWTH PHASE: ABSENT PRECURSOR LESION: NOT IDENTIFIED MARGINS: #	DP
MMVGP	MALIGNANT MELANOMA TYPE: # ANATOMIC LEVEL: # GREATEST THICKNESS: # MM MITOSES: # PER SQUARE MM ULCERATION: ABSENT RADIAL GROWTH PHASE: # VERTICAL GROWTH PHASE: PRESENT: PRECURSOR LESION: NOT IDENTIFIED MARGINS: # TUMOR INFILTRATING LYMPHOCYTES: ABSENT NEURAL INVASION: ABSENT VASCULAR INVASION: ABSENT REGRESSION: ABSENT MICROSATELLITES: ABSENT	DP
MNGC	MULTINUCLEATE GIANT CELLS	DP
MOLC	MOLLUSCUM CONTAGIOSUM.	DP
MOLCMLE	MOLLUSCUM CONTAGIOSUM, MULTIPLE LEVELS EXAMINED.	DP
NACL	NAIL (#), CLIPPINGS:	DP
NACLON	NAIL (#), CLIPPINGS: ONYCHOMYCOSIS.	DP
NDAR	NO DIAGNOSTIC ABNORMALITY RECOGNIZED.	DP
NDARMLE	NO DIAGNOSTIC ABNORMALITY RECOGNIZED, MULTIPLE LEVELS EXAMINED.	DP
NEVS	NEVUS SEBACEUS.	DP
NF	NEUROFIBROMA.	DP
NFMLE	NEUROFIBROMA, MULTIPLE LEVELS EXAMINED.	DP
NFPAM	NEUROFIBROMA, PRESENT AT MARGIN.	DP
NFPAMMLE	NEUROFIBROMA, PRESENT AT MARGINS, MULTIPLE LEVELS EXAMINED.	DP
NLD	NECROBIOSIS LIPOIDICA.	DP
NLDMLE	NECROBIOSIS LIPOIDICA, MULTIPLE LEVELS EXAMINED.	DP
NLS	NEVUS LIPOMATOSUS SUPERFICIALIS.	DP
NLSMLE	NEVUS LIPOMATOSIS SUPERFICIALIS, MULTIPLE LEVELS EXAMINED.	DP
NOFUN	No fungal organisms are identified with PASD stain.	DP
NOFUNU	NO FUNGAL ORGANISMS ARE IDENTIFIED WITH PASD STAIN.	DP
NSID	No specific immunoreactants are detected with regents for IgA, IgG, IgG(whole), IgM, C3, albumin, nor fibrinogen/fibrinogen split products.	DP
OAKN	SKIN (RIGHT DISTAL LEG), BIOPSY: NO DIAGNOSTIC ABNORMALITY RECOGNIZED (SEE NOTE). Note: A Congo red stain is negative for the presence of amyloid.	DP
ONY	ONYCHOMYCOSIS.	DP
ONYMLE	ONYCHOMYCOSIS, MULTIPLE LEVELS EXAMINED.	DP
ONYPAS	NAIL (), CLIPPING: ONYCHOMYCOSIS (SEE NOTE). Note: A PAS stain confirms the presence of microorganisms.	DP
OSH	outside hospital	DP
PADLM	PRESENT AT THE DEEP AND LATERAL MARGINS.	DP
PADM	PRESENT AT THE DEEP MARGIN.	DP
PAEM	PRESENT AT END MARGIN.	DP
PAIM	PRESENT AT INKED MARGINS.	DP
PALM	PRESENT AT LATERAL MARGIN.	DP
PAM	PRESENT AT MARGIN.	DP
PAMMLE	PRESENT AT MARGIN, MULTIPLE LEVELS EXAMINED.	DP
PASM	PRESENT AT SIDE MARGIN.	DP
PCR	polymerase chain reaction (PCR) technique.	DP
PEH	PSEUDOEPITHELIOMATOUS HYPERPLASIA.	DP
PEN	PALISADED ENCAPSULATED NEUROMA.	DP
PENMLE	PALISADED ENCAPSULATED NEUROMA, MULTIPLE LEVELS EXAMINED.	DP
PG	PYODERMA GANGRENOSUM.	DP
PGMLE	PYOGENIC GRANULOMA, MULTIPLE LEVELS EXAMINED.	DP
PGRAN	PYOGENIC GRANULOMA	DP
PILC	SKIN (), EXCISION: PILAR CYST.	DP
PILCMLE	SKIN (), EXCISION: PILAR CYST, MULTIPLE LEVELS EXAMINED.	DP
PILCR	SKIN (), EXCISION: PILAR CYST, RUPTURED.	DP
PILI	PERINFUNDIBULAR LYMPHOCYTIC INFILTRATE	DP
PILOS	SKIN (), EXCISION: PILONIDAL SINUS.	DP
PIM	PRESENT IN MARGINS.	DP
PIMMLE	PRESENT IN MARGINS, MULTIPLE LEVELS EXAMINED.	DP
PIP	POST-INFLAMMATORY PIGMENTATION	DP
PIPMLE	POST-INFLAMMATORY PIGMENTATION, MULTIPLE LEVELS EXAMINED.	DP
PK	PARAKERATOSIS	DP
PLC	PITYRIASIS LICHENOIDES CHRONICA.	DP
PLCMLE	PITYRIASIS LICHENOIDES CHRONICA, MULTIPLE LEVELS EXAMINED.	DP
PLEVA	PITYRIASIS LICHENOIDES ET VARIOLIFORMIS ACUTA.	DP
PLM	PIGMENT-LADEN MACROPHAGES	DP
PMMLE	PILOMATRICOMA, MULTIPLE LEVELS EXAMINED.	DP
PMN	POLYMORPHONUCLEAR CELLS	DP
PNB	PRESENT, NON-BRISK	DP
PNI	PERINEURAL INVASION	DP
PR	PITYRIASIS ROSEA.	DP
PRMLE	PITYRIASIS ROSEA, MULTIPLE LEVELS EXAMINED.	DP
PRP	PITYRIASIS RUBRA PILARIS.	DP
PRPMLE	PITYRIASIS RUBRA PILARIS, MULTIPLE LEVELS EXAMINED.	DP
PSCN	PIGMENTED SPINDLE CELL NEVUS.	DP
PSCNCE	PIGMENTED SPINDLE CELL NEVUS, COMPLETELY EXCISED.	DP
PSCNCEMLE	PIGMENTED SPINDLE CELL NEVUS, COMPLETELY EXCISED, MULTIPLE LEVELS EXAMINED.	DP
PSCNMLE	PIGMENTED SPINDLE CELL NEVUS, MULTIPLE LEVELS EXAMINED.	DP
PSCNPAMMEL	PIGMENTED SPINDLE CELL NEVUS, PRESENT AT MARGINS, MULTIPLE LEVELS EXAMINED.	DP
PSOD	PSORIASIFORM DERMATITIS.	DP
PSOH	PSORIASIFORM HYPERPLASIA	DP
PX	PILOMATRICOMA.	DP
PXE	PSEUDOXANTHOMA ELASTICUM.	DP
RBCCS	RESIDUAL BASAL CELL CARCINOMA, SUPERFICIAL TYPE.	DP
RLM	RESIDUAL LENTIGO MALIGNA	DP
SCARC	SCAR, CONSISTENT WITH PRIOR SURGICAL PROCEDURE.	DP
SCARCMLE	SCAR, CONSISTENT WITH PRIOR SURGICAL PROCEDURE, MULTIPLE LEVELS EXAMINED.	DP
SCARCNRAMP	1. SCAR, CONSISTENT WITH PRIOR SURGICAL PROCEDURE. 2. THERE IS NO EVIDENCE OF RESIDUAL ATYPICAL MELANOCYTIC PROLIFERATION.	DP
SCARCNRAMPMLE	1. SCAR, CONSISTENT WITH PRIOR SURGICAL PROCEDURE. 2. THERE IS NO EVIDENCE OF RESIDUAL ATYPICAL MELANOCYTIC PROLIFERATION, MULTIPLE LEVELS EXAMINED.	DP
SCARCNRBCC	1. SCAR, CONSISTENT WITH PRIOR SURGICAL PROCEDURE. 2. THERE IS NO EVIDENCE OF RESIDUAL BASAL CELL CARCINOMA.	DP
SCARCNRBCC	1. SCAR, CONSISTENT WITH PRIOR SURGICAL PROCEDURE. 2. THERE IS NO EVIDENCE OF RESIDUAL BASAL CELL CARCINOMA.	DP
SCARCNRBCCMLE	1. SCAR, CONSISTENT WITH PRIOR SURGICAL PROCEDURE. 2. THERE IS NO EVIDENCE OF RESIDUAL BASAL CELL CARCINOMA, MULTIPLE LEVELS EXAMINED.	DP
SCARCNRBCCMLE	1. SCAR, CONSISTENT WITH PRIOR SURGICAL PROCEDURE. 2. THERE IS NO EVIDENCE OF RESIDUAL BASAL CELL CARCINOMA, MULTIPLE LEVELS EXAMINED.	DP
SCARCNRMM	1. SCAR, CONSISTENT WITH PRIOR SURGICAL PROCEDURE. 2. THERE IS NO EVIDENCE OF RESIDUAL MALIGNANT MELANOMA.	DP
SCARCNRMMIS	1. SCAR, CONSISTENT WITH PRIOR SURGICAL PROCEDURE. 2. THERE IS NO EVIDENCE OF RESIDUAL MALIGNANT MELANOMA IN SITU.	DP
SCARCNRMMISMLE	1. SCAR, CONSISTENT WITH PRIOR SURGICAL PROCEDURE. 2. THERE IS NO EVIDENCE OF RESIDUAL MALIGNANT MELANOMA IN SITU, MULTIPLE LEVELS EXAMINED.	DP
SCARCNRMMMLE	1. SCAR, CONSISTENT WITH PRIOR SURGICAL PROCEDURE. 2. THERE IS NO EVIDENCE OF RESIDUAL MALIGNANT MELANOMA, MULTIPLE LEVELS EXAMINED.	DP
SCARCNRSCC	1. SCAR, CONSISTENT WITH PRIOR SURGICAL PROCEDURE. 2. THERE IS NO EVIDENCE OF RESIDUAL SQUAMOUS CELL CARCINOMA.	DP
SCARCNRSCCIS	1. SCAR, CONSISTENT WITH PRIOR SURGICAL PROCEDURE. 2. THERE IS NO EVIDENCE OF RESIDUAL SQUAMOUS CELL CARCINOMA IN SITU.	DP
SCARCNRSCCMLE	1. SCAR, CONSISTENT WITH PRIOR SURGICAL PROCEDURE. 2. THERE IS NO EVIDENCE OF RESIDUAL SQUAMOUS CELL CARCINOMA, MULTIPLE LEVELS EXAMINED.	DP
SCARCNSCC	1. SCAR, CONSISTENT WITH PRIOR SURGICAL PROCEDURE. 2. THERE IS NO EVIDENCE OF SQUAMOUS CELL CARCINOMA.	DP
SCARCNSCCMLE	1. SCAR, CONSISTENT WITH PRIOR SURGICAL PROCEDURE. 2. THERE IS NO EVIDENCE OF SQUAMOUS CELL CARCINOMA, MULTIPLE LEVELS EXAMINED.	DP
SCARCTINEM	1. SCAR, CONSISTENT WITH PRIOR SURGICAL PROCEDURE. 2. THERE IS NO EVIDENCE OF MALIGNANCY.	DP
SCARCTINEMM	1. SCAR, CONSISTENT WITH PRIOR SURGICAL PROCEDURE. 2. THERE IS NO EVIDENCE OF MALIGNANT MELANOMA.	DP
SCARCTINEMMIS	1. SCAR, CONSISTENT WITH PRIOR SURGICAL PROCEDURE. 2. THERE IS NO EVIDENCE OF MALIGNANT MELANOMA IN SITU.	DP
SCARCTINEMMLE	1. SCAR, CONSISTENT WITH PRIOR SURGICAL PROCEDURE. 2. THERE IS NO EVIDENCE OF MALIGNANCY IN MULTIPLE LEVELS EXAMINED.	DP
SCARCTINEMMMLE	1. SCAR, CONSISTENT WITH PRIOR SURGICAL PROCEDURE. 2. THERE IS NO EVIDENCE OF METASTATIC MALIGNANT MELANOMA IN MULTIPLE LEVELS EXAMINED.	DP
SCCIS	SQUAMOUS CELL CARCINOMA IN SITU.	DP
SCCISCE	SQUAMOUS CELL CARCINOMA IN SITU, COMPLETELY EXCISED.	DP
SCCISCEMLE	SQUAMOUS CELL CARCINOMA IN SITU, COMPLETELY EXCISED, MULTIPLE LEVELS EXAMINED.	DP
SCCISEXNEGMLE	SQUAMOUS CELL CARCINOMA IN SITU EXAMINED INKED MARGINS ARE FREE OF SQUAMOUS CELL CARCINOMA, MULTIPLE LEVELS EXAMINED.	DP
SCCISEXNEGSCC	SQUAMOUS CELL CARCINOMA IN SITU, EXAMINED INKED MARGINS ARE FREE OF SQUAMOUS CELL CARCINOMA.	DP
SCCISMLE	SQUAMOUS CELL CARCINOMA IN SITU, MULTIPLE LEVELS EXAMINED.	DP
SCCISPAM	SQUAMOUS CELL CARCINOMA IN SITU, PRESENT AT MARGIN.	DP
SCCISPAMMLE	SQUAMOUS CELL CARCINOMA IN SITU, PRESENT AT MARGIN, MULTIPLE LEVELS EXAMINED.	DP
SCCISSCC	CONSISTENT WITH SQUAMOUS CELL CARCINOMA IN SITU (SEE NOTE). Note: This carcinoma extends to the base of the biopsy specimen, invasive squamous cell carcinoma cannot be entirely excluded.	DP
SCCISSCCMLE	CONSISTENT WITH SQUAMOUS CELL CARCINOMA IN SITU, MULTIPLE LEVELS EXAMINED (SEE NOTE). Note: This carcinoma extends to the base of the biopsy specimen, invasive squamous cell carcinoma cannot be entirely excluded.	DP
SCCISSCCPAM	CONSISTENT WITH SQUAMOUS CELL CARCINOMA IN SITU, PRESENT AT MARGIN (SEE NOTE). Note: This carcinoma extends to the base of the biopsy specimen, invasive squamous cell carcinoma cannot be entirely excluded.	DP
SCCISSCCPAMMLE	CONSISTENT WITH SQUAMOUS CELL CARCINOMA IN SITU PRESENT AT MARGIN, MULTIPLE LEVELS EXAMINED (SEE NOTE). Note: This carcinoma extends to the base of the biopsy specimen, invasive squamous cell carcinoma cannot be entirely excluded.	DP
SCCM	SQUAMOUS CELL CARCINOMA, MODERATELY DIFFERENTIATED, INVASIVE.	DP
SCCMCE	SQUAMOUS CELL CARCINOMA, MODERATELY DIFFERENTIATED, INVASIVE, COMPLETELY EXCISED.	DP
SCCMCEMLE	SQUAMOUS CELL CARCINOMA, MODERATELY DIFFERENTIATED, INVASIVE, COMPLETELY EXCISED, MULTIPLE LEVELS EXAMINED.	DP
SCCMEXNEGSCC	SQUAMOUS CELL CARCINOMA, MODERATELY DIFFERENTIATED, INVASIVE. EXAMINED INKED MARGINS ARE FREE OF SQUAMOUS CELL CARCINOMA.	DP
SCCMEXNEGSCCMLE	SQUAMOUS CELL CARCINOMA, MODERATELY DIFFERENTIATED, INVASIVE. EXAMINED INKED MARGINS ARE FREE OF SQUAMOUS CELL CARCINOMA, MULTIPLE LEVELS EXAMINED.	DP
SCCMLE	SQUAMOUS CELL CARCINOMA, MULTIPLE LEVELS EXAMINED.	DP
SCCMMLE	SQUAMOUS CELL CARCINOMA, MODERATELY DIFFERENTIATED, INVASIVE, MULTIPLE LEVELS EXAMINED.	DP
SCCMP	SQUAMOUS CELL CARCINOMA, MODERATELY TO POORLY DIFFERENTIATED, INVASIVE.	DP
SCCMPAM	SQUAMOUS CELL CARCINOMA, MODERATELY DIFFERENTIATED, INVASIVE, PRESENT AT MARGIN.	DP
SCCMPCEMLE	SQUAMOUS CELL CARCINOMA, MODERATELY TO POORLY DIFFERENTIATED, INVASIVE, COMPLETELY EXCISED, MULTIPLE LEVELS EXAMINED.	DP
SCCMPMLE	SQUAMOUS CELL CARCINOMA, MODERATELY TO POORLY DIFFERENTIATED, INVASIVE, MULTIPLE LEVELS EXAMINED.	DP
SCCMW	SQUAMOUS CELL CARCINOMA, MODERATELY TO WELL DIFFERENTIATED, INVASIVE.	DP
SCCMWCE	SQUAMOUS CELL CARCINOMA, MODERATELY TO WELL DIFFERENTIATED, INVASIVE, COMPLETELY EXCISED.	DP
SCCMWCEMLE	SQUAMOUS CELL CARCINOMA, MODERATELY TO WELL DIFFERENTIATED, INVASIVE, COMPLETELY EXCISED, MULTIPLE LEVELS EXAMINED.	DP
SCCMWEXNEGSCC	SQUAMOUS CELL CARCINOMA, MODERATELY TO WELL DIFFERENTIATED, INVASIVE. EXAMINED INKED MARGINS ARE FREE OF SQUAMOUS CELL CARCINOMA.	DP
SCCMWMLE	SQUAMOUS CELL CARCINOMA, MODERATELY TO WELL DIFFERENTIATED, INVASIVE, MULTIPLE LEVELS EXAMINED.	DP
SCCMWPAM	SQUAMOUS CELL CARCINOMA, MODERATELY TO WELL DIFFERENTIATED, INVASIVE, PRESENT AT MARGIN.	DP
SCCP	SQUAMOUS CELL CARCINOMA, POORLY DIFFERENTIATED, INVASIVE.	DP
SCCPMLE	SQUAMOUS CELL CARCINOMA, POORLY DIFFERENTIATED, INVASIVE, MULTIPLE LEVELS EXAMINED.	DP
SCCPPAMMLE	SQUAMOUS CELL CARCINOMA, POORLY DIFFERENTIATED, INVASIVE, PRESENT AT MARGINS, MULTIPLE LEVELS EXAMINED.	DP
SCCW	SQUAMOUS CELL CARCINOMA, WELL DIFFERENTIATED, INVASIVE.	DP
SCCWCE	SQUAMOUS CELL CARCINOMA, WELL DIFFERENTIATED, INVASIVE, COMPLETELY EXCISED.	DP
SCCWCEMLE	SQUAMOUS CELL CARCINOMA, WELL DIFFERENTIATED, INVASIVE, COMPLETELY EXCISED, MULTIPLE LEVELS EXAMINED.	DP
SCCWEXNEGSCCMLE	SQUAMOUS CELL CARCINOMA, WELL DIFFERENTIATED, INVASIVE, EXAMINED INKED MARGINS ARE FREE OF SQUAMOUS CELL CARCINOMA, MULTIPLE LEVELS EXAMINED.	DP
SCCWMLE	SQUAMOUS CELL CARCINOMA, WELL DIFFERENTIATED, INVASIVE, MULTIPLE LEVELS EXAMINED.	DP
SCCWPAM	SQUAMOUS CELL CARCINOMA, WELL DIFFERENTIATED, INVASIVE, PRESENT AT MARGIN.	DP
SCCWPAMMLE	SQUAMOUS CELL CARCINOMA, WELL DIFFERENTIATED, INVASIVE, PRESENT AT MARGIN, MULTIPLE LEVELS EXAMINED.	DP
SDPLEI	SUPERFICIAL AND DEEP PERIVASCULAR LYMPHOEOSINOPHILIC INFILTRATE	DP
SDPLI	SUPERFICIAL AND DEEP PERIVASCULAR LYMPHOCYTIC INFILTRATE	DP
SEBH	SEBACEOUS HYPERPLASIA	DP
SEBHMLE	SEBACEOUS HYPERPLASIA, MULTIPLE LEVELS EXAMINED.	DP
SK	SEBORRHEIC KERATOSIS.	DP
SKB	SKIN (#), BIOPSY:	DP
SKCI	SKIN (FORESKIN), CIRCUMCISION:	DP
SKCU	SKIN (), CURETTAGE:	DP
SKE	SKIN (), EXCISION:	DP
SKEB	SKIN (), EXCISIONAL BIOPSY:	DP
SKIF	SEBORRHEIC KERATOSIS, INFLAMED.	DP
SKIFMLE	SEBORRHEIC KERATOSIS, INFLAMED, MULTIPLE LEVELS EXAMINED.	DP
SKII	SEBORRHEIC KERATOSIS, IRRITATED AND INFLAMED.	DP
SKIIMLE	SEBORRHEIC KERATOSIS, IRRITATED AND INFLAMED, MULTIPLE LEVELS EXAMINED.	DP
SKIR	SEBORRHEIC KERATOSIS, IRRITATED.	DP
SKIRMLE	SEBORRHEIC KERATOSIS, IRRITATED, MULTIPLE LEVELS EXAMINED.	DP
SKMLE	SEBORRHEIC KERATOSIS, MULTIPLE LEVELS EXAMINED.	DP
SKPAM	SEBORRHEIC KERATOSIS, PRESENT AT MARGIN.	DP
SKPB	SKIN (), PUNCH BIOPSY:	DP
SKPE	SKIN (), PUNCH EXCISION:	DP
SKRE	SKIN (), RE-EXCISION:	DP
SKSB	SKIN (), SHAVE BIOPSY:	DP
SKSE	SKIN (), SHAVE EXCISION:	DP
SKWE	SKIN (), WIDE EXCISION:	DP
SLE	SYSTEMIC LUPUS ERYTHEMATOSUS.	DP
SLNN	LYMPH NODE (SENTINEL #), EXCISION: THERE IS NO EVIDENCE OF METASTATIC MELANOMA IN ONE LYMPH NODE (0/1) (SEE NOTE). Note: No evidence of metastatic melanoma is observed with levels and immunohistochemical stains for S100 and MART-1.	DP
SLNP	LYMPH NODE (SENTINEL #), EXCISION: METASTATIC MELANOMA IS OBSERVED IN ONE LYMPH NODE (1/1) (SEE NOTE). Note: Metastatic melanoma is identified with levels and immunohistochemical stains for S100 and MART-1.	DP
SOLE	SOLAR ELASTOSIS.	DP
SOLEMLE	SOLAR ELASTOSIS, MULTIPLE LEVELS EXAMINED.	DP
SPAK	SPREADING PIGMENTED ACTINIC KERATOSIS.	DP
SPAKCE	SPREADING PIGMENTED ACTINIC KERATOSIS, COMPLETELY EXCISED.	DP
SPAKMLE	SPREADING PIGMENTED ACTINIC KERATOSIS, MULTIPLE LEVELS EXAMINED.	DP
SPLEI	SUPERFICIAL PERIVASCULAR LYMPHOEOSINOPHILIC INFILTRATE	DP
SPLHEI	SUPERFICIAL PERIVASCULAR LYMPHOHISTIOCYTIC AND EOSINOPHILIC INFILTRATE	DP
SPLHI	SUPERFICIAL PERIVASCULAR LYMPHOHISTIOCYTIC INFILTRATE	DP
SPLI	SUPERFICIAL PERIVASCULAR LYMPHOCYTIC INFILTRATE	DP
SPLIMLE	SUPERFICIAL PERIVASCULAR LYMPHOCYTIC INFILTRATE, MULTIPLE LEVELS EXAMINED.	DP
SPOD	SPONGIOTIC DERMATITIS	DP
SPOID	SPONGIOTIC INTERFACE DERMATITIS	DP
SPOPSOD	SPONGIOTIC PSORIASIFORM DERMATITIS.	DP
SSNS	Special stains are not a sensitive means of detecting microorganisms. Culture is recommended.	DP
SSSS	STAPHYLOCOCCUS SCALDED SKIN SYNDROME	DP
STAD	STASIS DERMATITIS.	DP
STADMLE	STASIS DERMATITIS, MULTIPLE LEVELS EXAMINED.	DP
STM	SLIGHT TO MODERATE	DP
TEN	TOXIC EPIDERMAL NECROLYSIS.	DP
TEPI	TRICHOEPITHELIOMA.	DP
TEPIMLE	TRICHOEPITHELIOMA, MULTIPLE LEVELS EXAMINED.	DP
TIFD	TISSUE INSUFFICIENT FOR DIAGNOSIS.	DP
TINEAMP	THERE IS NO EVIDENCE OF ATYPICAL MELANOCYTIC PROLIFERATION.	DP
TINEBCC	THERE IS NO EVIDENCE OF BASAL CELL CARCINOMA.	DP
TINEDYSN	THERE IS NO EVIDENCE OF DYSPLASTIC NEVUS.	DP
TINELM	THERE IS NO EVIDENCE OF LENTIGO MALIGNA.	DP
TINELMMLE	THERE IS NO EVIDENCE OF LENTIGO MALIGNA, MULTIPLE LEVELS EXAMINED.	DP
TINEMM	THERE IS NO EVIDENCE OF MALIGNANT MELANOMA.	DP
TINEMMLE	THERE IS NO EVIDENCE OF MALIGNANCY IN MULTIPLE LEVELS EXAMINED.	DP
TINEMMMLE	THERE IS NO EVIDENCE OF MALIGNANT MELANOMA IN MULTIPLE LEVELS EXAMINED.	DP
TINER	THERE IS NO EVIDENCE OF RESIDUAL	DP
TINERAMP	THERE IS NO EVIDENCE OF RESIDUAL ATYPICAL MELANOCYTIC PROLIFERATION.	DP
TINERAMPMLE	THERE IS NO EVIDENCE OF RESIDUAL ATYPICAL MELANOCYTIC PROLIFERATION, MULTIPLE LEVELS EXAMINED.	DP
TINERBCC	THERE IS NO EVIDENCE OF RESIDUAL BASAL CELL CARCINOMA.	DP
TINERBCCMLE	THERE IS NO EVIDENCE OF RESIDUAL BASAL CELL CARCINOMA, MULTIPLE LEVELS EXAMINED.	DP
TINERLCDN	THERE IS NO EVIDENCE OF RESIDUAL LENTIGINOUS COMPOUND DYSPLASTIC NEVUS.	DP
TINERLM	THERE IS NO EVIDENCE OF RESIDUAL LENTIGO MALIGNA.	DP
TINERMM	THERE IS NO EVIDENCE OF RESIDUAL MALIGNANT MELANOMA.	DP
TINERSCC	THERE IS NO EVIDENCE OF RESIDUAL SQUAMOUS CELL CARCINOMA.	DP
TINESCCMLE	THERE IS NO EVIDENCE OF SQUAMOUS CELL CARCINOMA, MULTIPLE LEVELS EXAMINED.	DP
TLEM	TRICHOLEMMOMA.	DP
TLEMMLE	TRICHOLEMMOMA, MULTIPLE LEVELS EXAMINED.	DP
TMEP	TELANGIECTASIA MACULARIS ERUPTIVA PERSTANS.	DP
UP	URTICARIA PIGMENTOSA	DP
VV	VERRUCA VULGARIS.	DP
VVMLE	VERRUCA VULGARIS, MULTIPLE LEVELS EXAMINED.	DP
XG	XANTHOGRANULOMATOUS	DP
ADENOIDS	Adenoids; gross exam only (see note). Note: gross only (GODIS) note.	ENT
CDC	Chronic dacryocystitis	ENT
CONNEG	Connective tissue; negative for malignancy.	ENT
CRS	Chronic rhinosinusitis.	ENT
CRSE	Chronic rhinosinusitis with abundant eosinophils.	ENT
CRSEN	Chronic rhinosinusitis with abundant eosinophils and allergic mucin (see note). Note: GMS (silver) stain to assess for fungus is being performed, and the results will be reported in an addendum.	ENT
FATI	Fibroadipose tissue	ENT
NEFO	Negative for malignancy.	ENT
NEFOC	Negative for carcinoma.	ENT
NEFOMD	Negative for malignancy or dysplasia.	ENT
NEFOP	Negative for papilloma.	ENT
NENE	Negative for neoplasia.	ENT
OSS	Consistent with ossicle; gross exam only (see note). NOTE: gross only (GODIS) note.	ENT
PCRS	Polypoid chronic rhinosinusitis.	ENT
PCRSE	Polypoid chronic rhinosinusitis with eosinophils.	ENT
PCRSEN	Polypoid chronic rhinosinusitis with eosinophils and allergic mucin (see note). Note: A GMS (silver) stain is being performed, and the results will be reported in an addendum.	ENT
SEPTUM	Bone and cartilage; gross exam only (see note). NOTE: gross only (GODIS) note.	ENT
SKEFO	Skeletal muscle and fibroconnective tisssue; negative for malignancy.	ENT
SKENO	Skeletal muscle; negative for malignancy.	ENT
SPCRS	Slightly polypoid chronic rhinosinusitis.	ENT
SQUEFO	Squamous mucosa; negative for malignancy.	ENT
SQUEFOC	Squamous mucosa; negative for carcinoma.	ENT
TINEP	There is no evidence of papilloma.	ENT
TONAD	Tonsils and adenoids; gross exam only (see note). NOTE: gross only (GODIS) note.	ENT
TONSIL	Tonsils; gross exam only (see note). NOTE: gross only (GODIS) note.	ENT
TONSILS	Tonsils; gross exam only (see note). NOTE: gross only (GODIS) note.	ENT
ACI	Acute and chronic inflammation	GEN
ACMI	Adenocarcinoma, moderately differentiated, invasive	GEN
ACPI	Adenocarcinoma, poorly differentiated, invasive	GEN
ACWI	Adenocarcinoma, well differentiated, invasive	GEN
ADCA	Adenocarcinoma	GEN
AFBAD	An AFB stain will be reported in an addendum.	GEN
AFBN	An AFB stain is negative for acid fast bacilli.	GEN
AI	Acute inflammation	GEN
AIS	Adenocarcinoma in situ	GEN
BHAD	A Brown Hopps stain for bacteria will be reported in an addendum.	GEN
BHN	A Brown Hopps stain for bacteria is negative.	GEN
BHP	A Brown Hopps stain for bacteria is positive.	GEN
CAUT	Cautery artifact precludes definitive interpretation	GEN
CCR	Clinical correlation is recommended	GEN
CE	completely excised	GEN
CHMNS	The changes are mild and non-specific.	GEN
CHNS	The changes are non-specific.	GEN
CI	Chronic inflammation	GEN
CLINCO	Clinical correlation is suggested.	GEN
CMV	cytomegalovirus	GEN
CMVAD	An immunohistochemical stain for CMV will be reported in an addendum.	GEN
CMVN	An immunohistochemical stain for CMV is negative.	GEN
CMVP	An immunohistochemical stain for CMV is positive	GEN
COMP	Comparison to the prior biopsy	GEN
CW	consistent with	GEN
EBV	Epstein-Barr virus	GEN
FBGCR	foreign body giant cell reaction	GEN
FBGCRP	Foreign body giant cell reaction to polarizing material.	GEN
FEP	FIBROEPITHELIAL POLYP.	GEN
FO	fragment of	GEN
FPE	fibrinopurulent exudate	GEN
FSDAC	The frozen section diagnoses are confirmed.	GEN
FSDIC	The frozen section diagnosis is confirmed.	GEN
FSO	fragments of	GEN
GMSAD	A GMS stain for fungus will be reported in an addendum.	GEN
GMSAFBED	GMS and AFB stains will be reported in an addendum.	GEN
GMSAFBN	GMS and AFB stains are negative.	GEN
GMSN	A GMS stain is negative for fungus.	GEN
GMSP	A GMS stain is positive	GEN
GODIS	Note: This specimen has been subjected to a gross examination only. If it is desired that this specimen be processed for additional studies, particularly microscopic examination, please contact the case pathologist. Requests must be received within two weeks of the date of this report, as these specimens are routinely discarded after a prescribed period of time.	GEN
GRDNR	The tumor grade in this limited sample may not be representative of the entire lesion	GEN
GT	Granulation tissue	GEN
GTAC	Granulation tissue with acute and chronic inflammation	GEN
HLM	Hemosiderin laden macrophages	GEN
HPV	human papillomavirus	GEN
HSV	herpes simplex virus	GEN
HSVAD	An immunohistochemical stain for HSV will be reported in an addendum.	GEN
HSVN	An immunohistochemical stain for HSV is negative. The stain is a cocktail of antibodies directed against HSV 1 and HSV 2.	GEN
HSVP	An immunohistochemical stain for HSV is positive. This test is an antibody cocktail that detects both HSV1 and HSV2.	GEN
ICE	incompletely excised	GEN
IHC	Immunohistochemistry	GEN
IHCAD	The following immunohistochemical stain is pending and will be reported in an addendum:	GEN
IHCMGH	Immunohistochemical studies performed at Massachusetts General Hospital reveal	GEN
IHCSAD	The following immunohistochemical stains are pending and will be reported in an addendum:	GEN
IMC	Intramucosal carcinoma	GEN
ISH	In-situ hybridization	GEN
KEEP	No unstained slides or paraffin blocks were received with this case. Because it is essential for a consultant to retain representative material for future reference, we are keeping one H&E slide for our files. If recuts are sent for representative blocks, we will return the original slides.	GEN
LAP	lamina propria	GEN
LEVAD	Additional levels will be performed and the result reported in an addendum.	GEN
MACA	metastatic adenocarcinoma	GEN
MGHIHC	Immunohistochemical stains performed at Massachusetts General Hospital reveal the following profile in the lesional cells:	GEN
MLE	multiple levels examined.	GEN
MM	malignant melanoma	GEN
MREVCASE	have reviewed the case, and agree with the diagnosis above.	GEN
MREVREP	have reviewed representative slides from this case, and agree with the diagnosis above.	GEN
MTM	mild to moderate	GEN
MTS	moderate to severe	GEN
NDAR	No diagnostic abnormality recognized.	GEN
NOREV	Not reviewed because not medically indicated	GEN
OMIF	The overal morphologic and immunophenotypic findings	GEN
OSHIHC	Immunohistochemical stains performed at the outside institution and reviewed at Massachusetts General Hospital reveal the following profile in the lesional cells:	GEN
PASDFAD	A PASd stain for fungus will be reported in an addendum.	GEN
PASDFN	A PASd stain for fungus is negative.	GEN
PASDFP	A PASd stain for fungus is positive.	GEN
PASFAD	A PAS stain for fungus will be reported in an addendum.	GEN
PASFN	A PAS stain for fungus is negative.	GEN
PASFP	A PAS stain for fungus is positive.	GEN
PREP	Prepared in our laboratory	GEN
PREPMGH	Prepared at Massachusetts General Hospital	GEN
PREPOSH	Prepared at the outside hospital or laboratory	GEN
PREPREF	Prepared at the referring institution	GEN
RAD	Changes consistent with radiation effect.	GEN
REA	reactive epithelial atypia	GEN
REF	This case is a reference case for additional studies performed on a prior specimen; please refer to the addendum of that case for the results (	GEN
REVCASE	has reviewed the case, and agrees with the diagnosis above.	GEN
REVREP	has reviewed representative slides from this case, and agrees with the diagnosis above.	GEN
SCC	Squamous cell carcinoma	GEN
SN	(see note).	GEN
SO	suggestive of	GEN
SSR	(see synoptic report)	GEN
TINE	There is no evidence	GEN
TINECL	There is no evidence of carcinoma.	GEN
TINEDA	There is no evidence of dysplasia in any of the biopsies.	GEN
TINEDC	There is no evidence of dysplasia or carcinoma.	GEN
TINEM	There is no evidence of malignancy.	GEN
TINEMD	There is no evidence of malignancy or dysplasia.	GEN
TINEN	There is no evidence of neoplasia.	GEN
TINME	There is no morphologic evidence of	GEN
ULC	ulceration/erosion	GEN
VINCN	Viral inclusions are not seen.	GEN
WNDA	with no diagnostic abnormality	GEN
XRT	Changes consistent with prior irradiation	GEN
ABOD	Acidophil bodies are	GI
ACC	Active chronic colitis	GI
ACCH	Acute and chronic cholecystitis.	GI
ACCHCH	Acute and chronic cholecystitis and cholelithiasis.	GI
ACG	Active chronic gastritis	GI
AESO	Active esophagitis	GI
AHPOL	Hyperplastic polyp with atypical features (see note). Note: Some features are suggestive but not diagnostic of a sessile serrated polyp/adenoma.	GI
AIN1	Low grade squamous intraepithelial lesion (AIN 1)	GI
AIN2	High grade squamous intraepithelial lesion (AIN 2)	GI
AIN3	High grade squamous intraepithelial lesion (AIN 3)	GI
ANM	Anal mucosa	GI
ANUS	Note: Ki67 and p16 immunostains were evaluated and support the diagnosis.	GI
APCM	Architecturally preserved colonic mucosa	GI
APX	Acute appendicitis	GI
ARM	Ano-rectal mucosa	GI
ASAP	Acute suppurative appendicitis and periappendicitis	GI
BARR	Glandular mucosa with focal intestinal metaplasia consistent with Barrett's esophagus.	GI
BARRC	Glandular mucosa with focal intesinal metaplasia. See note. Note: The morphology is consistent with Barrett's esophagus in the appropriate clinical setting.	GI
BCH	Basal cell hyperplasia	GI
BCHA	Basal cell hyperplasia is absent.	GI
BCHMA	Basal cell hyperplasia is marked.	GI
BCHMI	Basal cell hyperplasia is mild.	GI
BEIM	Barrett's esophagus with intestinal metaplasia	GI
BEIND	Barrett's esophagus with intestinal metaplasia and epithelial atypia, indefinite for dysplasia.	GI
BEND	Barrett's esophagus with intestinal metaplasia; no dysplasia is seen.	GI
BESO	Barrett's esophagus	GI
BGH	Brunner's gland hyperplasia	GI
CAG	Chronic antral gastritis	GI
CAT	Chronic atrophic gastritis	GI
CBBE	Note: If the biopsy was taken from the tubular esophagus and there is endoscopic evidence of esophageal columnar metaplasia extending at least 1 cm proximal to the GE junction, then the presence of intestinal metaplasia confirms the diagnosis of Barrett’s esophagus.	GI
CCH	Chronic cholecystitis	GI
CCHCH	Chronic cholecystitis and cholelithiasis	GI
CCHCHCH	Chronic cholecystitis with cholesterolosis and cholelithiasis.	GI
CCIB	Clinical correlation with distribution of disease is necessary to distinguish Crohn's disease from ulcerative colitis.	GI
CELD1	Mild villous atrophy with marked intraepithelial lymphocytosis consistent with celiac disease.	GI
CELD2	Moderate villous atrophy with marked intraepithelial lymphocytosis consistent with celiac disease.	GI
CELD3	Total villous atrophy with intraepithelial lymphocytosis consistent with celiac disease.	GI
CEP	The cauterized stalk/base appears free of adenomatous epithelium.	GI
CGAS	Chemical gastritis	GI
CHD	Crohn's disease	GI
CHEP	Mildly active chronic hepatitis with bridging fibrosis/evolving cirrhosis/cirrhosis consistent with hepatitis C.	GI
CHIC	Chronic inactive colitis	GI
CILP	Colonic mucosa with increased cellularity of the lamina propria.	GI
CLITH	cholelithiasis	GI
CMCD	Colonic mucosa with crypt architectural disarray	GI
CMH	Colonic mucosa with hyperplastic features.	GI
CMHC	Colonic mucosa with subtle hyperplastic changes.	GI
CMHLA	Colonic mucosa with hyperplastic lymphoid aggregate.	GI
CMLA	Colonic mucosa with lymphoid aggregate.	GI
CMMCD	Colonic mucosa with mild crypt architectural disarray	GI
COCA	Colocutaneous anastomosis	GI
COLM	Colonic mucosa	GI
CONF	Confluent necrosis is present; the presence of confluent necrosis in the setting of chronic viral hepatitis raises the possibility of HBeAg to Ab seroconversion, HCV acute exacerbation, HDV superinfection on HBV, HIV co-infection, or superimposed drug toxicity.	GI
COPAD	A histochemical stain for copper is pending and will be reported in an addendum.	GI
COPN	A histochemical stain for copper is negative.	GI
CQC	Chronic quiescent colitis	GI
CWEE	In a patient on adequate proton pump inhibition or with normal ph monitoring, the histological findings support the diagnosis of Eosinophilic Esophagitis (EoE).	GI
CWGERD	Presence of a sharp inflammatory gradient from proximal to distal esophagus suggests an element of injury secondary to gastroesophageal reflux disease (GERD).	GI
DALM	Dysplasia associated lesion or mass	GI
DIV	Diverticular disease	GI
DMIL	Duodenal mucosa with normal villous architecture and increased intraepithelial lymphocytes (see note). Note: the differential diagnosis includes gluten sensitivity or family history of gluten sensitivity, allergy to other food antigens, post-viral gastroenteritis, autoimmune enteropathy, bacterial overgrowth, immunodeficiency syndromes (CVID, IgA deficiency), and tropical sprue. These features have also been described in patients with a history of Crohn's disease, H. pylori gastritis, collagen vascular disease, or NSAID use.	GI
DMNV	Duodenal mucosa with normal villous architecture	GI
DMSIL	Duodenal mucosal with slight increase in intraepithelial lymphocytes. See note. Note: The presence of slightly increased intraepithelial lymphocytes is not specific, but correlation with clinical data and serologies is suggested to rule out celiac disease.	GI
DPOR	Portal tracts show XXX ductular duplication.	GI
DTIS	Diverticulitis	GI
DUM	Duodenal mucosa	GI
ECM	Edematous colonic mucosa	GI
EE10	Active esophagitis with peak intraepithelial eosinophil count of 10 per HPF.	GI
EE11	Active esophagitis with peak intraepithelial eosinophil count of 11 per HPF.	GI
EE12	Active esophagitis with peak intraepithelial eosinophil count of 12 per HPF.	GI
EE13	Active esophagitis with peak intraepithelial eosinophil count of 13 per HPF.	GI
EE14	Active esophagitis with peak intraepithelial eosinophil count of 14 per HPF.	GI
EE15	Active esophagitis with peak intraepithelial eosinophil count of 15 per HPF.	GI
EE16	Active esophagitis with peak intraepithelial eosinophil count of 16 per HPF.	GI
EE17	Active esophagitis with peak intraepithelial eosinophil count of 17 per HPF.	GI
EE18	Active esophagitis with peak intraepithelial eosinophil count of 18 per HPF.	GI
EE19	Active esophagitis with peak intraepithelial eosinophil count of 19 per HPF.	GI
EE2	Active esophagitis with peak intraepithelial eosinophils less than 3 per HPF.	GI
EE20	Active esophagitis with peak intraepithelial eosinophil count of 20 per HPF.	GI
EE21	Active esophagitis with peak intraepithelial eosinophil count of 21 per HPF.	GI
EE22	Active esophagitis with peak intraepithelial eosinophil count of 22 per HPF.	GI
EE23	Active esophagitis with peak intraepithelial eosinophil count of 23 per HPF.	GI
EE24	Active esophagitis with peak intraepithelial eosinophil count of 24 per HPF.	GI
EE25	Active esophagitis with peak intraepithelial eosinophil count of 25 per HPF.	GI
EE26	Active esophagitis with peak intraepithelial eosinophil count of 26 per HPF.	GI
EE27	Active esophagitis with peak intraepithelial eosinophil count of 27 per HPF.	GI
EE28	Active esophagitis with peak intraepithelial eosinophil count of 28 per HPF.	GI
EE29	Active esophagitis with peak intraepithelial eosinophil count of 29 per HPF.	GI
EE3	Active esophagitis with peak intraepithelial eosinophil count of 3 per HPF.	GI
EE30	Active esophagitis with peak intraepithelial eosinophil count of 30 per HPF.	GI
EE31	Active esophagitis with peak intraepithelial eosinophil count of 31 per HPF.	GI
EE32	Active esophagitis with peak intraepithelial eosinophil count of 32 per HPF.	GI
EE33	Active esophagitis with peak intraepithelial eosinophil count of 33 per HPF.	GI
EE34	Active esophagitis with peak intraepithelial eosinophil count of 34 per HPF.	GI
EE35	Active esophagitis with peak intraepithelial eosinophil count of 35 per HPF.	GI
EE36	Active esophagitis with peak intraepithelial eosinophil count of 36 per HPF.	GI
EE37	Active esophagitis with peak intraepithelial eosinophil count of 37 per HPF.	GI
EE38	Active esophagitis with peak intraepithelial eosinophil count of 38 per HPF.	GI
EE39	Active esophagitis with peak intraepithelial eosinophil count of 39 per HPF.	GI
EE4	Active esophagitis with peak intraepithelial eosinophil count of 4 per HPF.	GI
EE40	Active esophagitis with peak intraepithelial eosinophil count exceeding 40 per HPF.	GI
EE5	Active esophagitis with peak intraepithelial eosinophil count of 5 per HPF.	GI
EE6	Active esophagitis with peak intraepithelial eosinophil count of 6 per HPF.	GI
EE7	Active esophagitis with peak intraepithelial eosinophil count of 7 per HPF.	GI
EE8	Active esophagitis with peak intraepithelial eosinophil count of 8 per HPF.	GI
EE9	Active esophagitis with peak intraepithelial eosinophil count of 9 per HPF.	GI
EEAE	Eosinophilic esophagitis/allergic esophagitis	GI
EERE	Esophageal squamous mucosa with very rare intraepithelial eosinophils.	GI
EMAA	Eosinophilic microabscesses are absent.	GI
EMAP	Eosinophilic microabscesses are present.	GI
EOG	Eosinophilic gastritis	GI
ESM	Esophageal squamous mucosa	GI
ESON	A PASd is negative for fungi. A CMV stain is negative. An HSV stain is negative.	GI
ESONS	The findings are non-specific. Possible etiologies include chemical (including peptic), mechanical, or thermal injury.	GI
ESVINE	Immunohistochemical stains for CMV, HSV1, and HSV2 are negative.	GI
FAC	Focal active colitis.	GI
FACC	Focal active chronic colitis.	GI
FATM	Mild to moderate steatosis is present in a pattern consistent with HCV.	GI
FATT	Moderate to marked steatosis is present; concomitant toxic or metabolic injury cannot be excluded.	GI
FCM	Fragment of colonic mucosa	GI
FCRI	Focal cryptitis	GI
FGP	Fundic gland polyp	GI
FHPOL	Fragments of hyperplastic polyp	GI
FIB0	Trichrome stain shows no fibrosis (Ishak stage 0 of 6).	GI
FIB1	Trichrome stain shows fibrous expansion of some portal areas, with or without short fibrous septa (Ishak stage 1 of 6).	GI
FIB2	Trichrome stain shows fibrous expansion of most portal areas, with or without short fibrous septa (Ishak stage 2 of 6).	GI
FIB3	Trichrome stain shows fibrous expansion of most portal areas, with occasional portal to portal bridging (Ishak stage 3 of 6).	GI
FIB4	Trichrome stain shows fibrous expansion of most portal areas, with marked portal to portal bridging as well as portal to central bridging (Ishak stage 4 of 6).	GI
FIB5	Trichrome stain shows marked bridging fibrosis with occasional nodules (incomplete cirrhosis) (Ishak stage 5 of 6).	GI
FIB6	Trichrome stain shows probable or definite cirrhosis (Ishak stage 6 of 6).	GI
FLD	Fatty liver disease	GI
FOHYP	Foveolar hyperplasia	GI
FOMET	Foveolar metaplasia	GI
FSCM	Fragments of colonic mucosa	GI
FSSA	Fragments of sessile serrated adenoma/polyp.	GI
FTAD	Fragments of tubular adenoma	GI
FTVA	Fragments of tubulovillous adenoma	GI
FUCM	Fragments of unremarkable colonic mucosa	GI
FVAD	Fragments of villous adenoma	GI
GABTM	Gastric antral-body transitional mucosa	GI
GACA	Gastrocutaneous anastomosis	GI
GAM	Gastric antral mucosa	GI
GAMPC	Gastric antral mucosa with slight increase in lamina propria plasma cells.	GI
GASM	Gastric mucosa	GI
GAVE	Gastric antral vascular ectasia	GI
GBFM	Gastric body/fundic type mucosa	GI
GBOM	Gastric body mucosa	GI
GCM	Gastric cardiac-type mucosa	GI
GEJCC	Gastroesophageal junctional mucosa with chronic carditis. No intestinal metaplasia seen.	GI
GEJFIM	Gastroesophageal junctional mucosa with focal intestinal metaplasia.	GI
GEJIM	Gastroesophageal junctional mucosa with intestinal metaplasia.	GI
GEJM	Gastroesophageal junctional mucosa	GI
GENI	Investigation for a genetic iron disorder is suggested.	GI
GFIM	Glandular mucosa with focal intestinal metaplasia. Note: Could be Barrett's. No dysplasia.	GI
GFM	Gastric fundic mucosa	GI
GGL	Ground glass hepatocytes are present.	GI
GIM	Glandular mucosa with intestinal metaplasia. Note: Could be Barrett's. No dysplasia.	GI
GLAP	Granulation tissue in the lamina propria	GI
GLFIM	Glandular mucosa with focal intestinal metaplasia.	GI
GLIM	Glandular mucosa with intestinal metaplasia.	GI
GLYN	Glycogenated nuclei are	GI
HBAL	Hepatocyte ballooning is	GI
HGD	High grade dysplasia	GI
HIRS	Hirschsprung disease	GI
HPG	Helicobacter pylori gastritis	GI
HPHEN	No organisms consistent with Helicobacter pylori are seen on hematoxylin and eosin stained slides.	GI
HPHEP	Organisms consistent with Helicobacter pylori are seen on hematoxylin and eosin stained slides.	GI
HPIAD	An immunohistochemical stain for Helicobacter pylori is pending and will be reported in an addendum.	GI
HPIN	An immunohistochemical stain for H. pylori is negative.	GI
HPIP	An immunostain for H. pylori is positive.	GI
HPOL	Hyperplastic polyp	GI
IBD	inflammatory bowel disease	GI
IBDN	All tissue fragments are affected. No granulomas are seen and no dysplasia is present. The findings are consistent with inflammatory bowel disease if specific etiologies are excluded clinically.	GI
IDEF	NOTE: The fragmented nature of the specimen precludes evaluation for completeness of excision.	GI
IDES	NOTE: The completeness of excision cannot be determined because the polyp base/stalk is not visualized.	GI
IEEO	Intraepithelial eosinophils	GI
IEL	Intraepithelial lymphocytes	GI
IEN	Intraepithelial neutrophils	GI
IFP	Inflammatory fibroid polyp	GI
ILCA	Ileocutaneous anastomosis	GI
ILCOA	Ileocolonic anastomosis	GI
ILHPP	Ileal mucosa with hyperplastic Peyer's patches.	GI
ILM	Ileal mucosa	GI
ILOB	Lobular inflammation is XXX the inflammation consists of	GI
IM	Intestinal metaplasia	GI
IMHV	Immunohistochemical stains for HBsAg and HBcAg are pending and will be reported in an addendum.	GI
IND	Intestinal neuronal dysplasia	GI
INDEE	The histological features are indeterminate with respect to the etiology of this patient's esophagitis. Correlation with clinical data and treatment status is required to differentiate gastroesophageal reflux disease (GERD) from Eosinophilic Esophagitis (EoE).	GI
INDY	Indefinite for dysplasia	GI
INFP	Inflammatory polyp	GI
IPOR	Portal tracts show XXX inflammation.	GI
IPP	Inflammatory pseudopolyp	GI
IRON1	Iron stain shows 1+ iron in hepatocytes.	GI
IRON2	Iron stain shows 2+ iron in hepatocytes.	GI
IRON3	Iron stain shows 3+ iron in hepatocytes.	GI
IRON4	Iron stain shows 4+ iron in hepatocytes.	GI
IRONK	Iron stain shows increased iron in Kupffer cells.	GI
IRONN	Iron stain is negative.	GI
ISCH	Ischemic colitis	GI
ISCHN	Note: The differential diagnosis includes mesenteric vascular disease, embolic disease, vasoactive and/or volume-depleting drug effect, vasculitis, shock and other low flow states, and infection by Shiga-like toxin-producing organisms such as enterohemorrhagic E. coli. No cholesterol emboli or small vessel vasculitis is seen.	GI
JPOL	Juvenile polyp	GI
LAP	Lamina propria	GI
LCOL	Lymphocytic colitis	GI
LGAS	Lymphocytic gastritis	GI
LIGR	Lipogranulomas are observed in the	GI
LPI	Lymphoplasmacytic infiltrate	GI
MBOD	Mallory bodies are	GI
MCCHCH	Mild chronic cholecystitis and cholelithiasis.	GI
MCOL	Microscopic colitis	GI
MEGA	Megamitochondria are	GI
MELC	Melanosis coli	GI
MIC	Mildly active colitis	GI
MICC	Mildly active chronic colitis	GI
MIGC	Mildly active granulomatous colitis.	GI
MNGAS	Mild chronic non-specific gastritis	GI
MOC	Moderately active colitis	GI
MOCC	Moderately active chronic colitis	GI
MOGC	Moderately active granulomatous colitis.	GI
MUP	Mucosal prolapse changes	GI
MUPP	Mucosal prolapse polyp	GI
NAFLD	Non-alcoholic fatty liver disease	GI
NCOL	Colonic mucosa with no diagnostic abnormality.	GI
NCWEE	The histological findings are not consistent with untreated Eosinophilic Esophagitis (EoE).	GI
NDUO	Duodenal mucosa with no diagnostic abnormality	GI
NECR	Hepatocyte necrosis is	GI
NESO	Esophageal squamous mucosa with no diagnostic abnormality.	GI
NGABFM	Gastric antral and body/fundic mucosa with no diagnostic abnormality recognized.	GI
NGABTM	Gastric antral-body transitional mucosa with no diagnostic abnormality recognized.	GI
NGAM	Gastric antral mucosa with no diagnostic abnormality.	GI
NGAS	Chronic non-specific gastritis	GI
NGBFM	Gastric body/fundic mucosa with no diagnostic abnormality recognized.	GI
NGBFS	Segment of gastric body/fundus with no diagnostic abnormality recognized.	GI
NGBM	Gastric body mucosa with no diagnostic abnormality recognized.	GI
NGCM	Gastric cardia mucosa with no diagnostic abnormality.	GI
NGEJM	Gastroesophageal junctional mucosa with no diagnostic abnormality.	GI
NGFM	Gastric fundic mucosa with no diagnostic abnormality.	GI
NHGD	No high-grade dysplasia is identified.	GI
NILM	Ileal mucosa with no diagnostic abnormality.	GI
NIPD	No iron or PAS/D positive globules are present.	GI
NJEJ	Jejunal mucosa with no diagnostic abnormality recognized.	GI
NODA	No dysplasia seen in any of the biopsies.	GI
NODGR	No dysplasia or granulomas seen.	GI
NOGR	No granulomas are seen.	GI
NOHP	Inflammatory changes suggestive of H. pylori infection are not present and organisms are not identified on routine stains.	GI
NOPB	No prior biopsy is available at this institution for comparison.	GI
NPLC	The inflammatory infiltrate contains numerous plasma cells.	GI
NSIM	Small intestinal mucosa with no diagnostic abnormality recognized.	GI
NSPC	No specific pathologic change.	GI
P16N	Immunohistochemical stain for p16 does not show block-like staining	GI
P16P	Immunohistochemical stain for p16 shows block-like positivity, supporting high grade squamous intraepithelial lesion	GI
PASD	PAS/D stain shows no intracytoplasmic globules.	GI
PBC	Primary biliary cholangitis	GI
PBNA	The prior biopsy is not available for review (XX	GI
PCH	Parietal cell hyperplasia	GI
PCM	Polypoid colonic mucosa	GI
PCMET	Paneth cell metaplasia	GI
PDL1	PD-L1 IMMUNOHISTOCHEMICAL STAINING: A multiplex stain for PD-L1/CD8 was performed. An immunostain for PD-L1 was performed. 100 or more tumor cells are available in the specimen. PD-L1 shows no membranous staining of tumor cells. PD-L1 shows membranous staining of [weak, moderate, strong, combinations of those] intensity in X % of tumor cells. CD8+ tumor infiltrating lymphocytes are absent or rare (score of 0). CD8+ tumor infiltrating lymphocytes are few and scattered, involving < 5% of tumor cells (score of 1). CD8+ tumor infiltrating lymphocytes are present, associated with 5-25% of tumor cells (score of 2). CD8+ tumor infiltrating lymphocytes are numerous, associated with > 25 % of tumor cells (score of 3).	GI
PEP	Duodenal mucosa with reactive epithelial and stromal changes consistent with peptic injury.	GI
PHP	Immunohistochemical stain for H. pylori is positive.	GI
PJP	Peutz-Jegher polyp	GI
PMAC	Pigmented macrophages in the lobules are	GI
PMLP	PAS/D stain shows positive macrophages in the	GI
PSC	Primary sclerosing cholangitis	GI
REFL	Reflux esophagitis	GI
ROID	Marked vascular ectasia consistent with hemorrhoids.	GI
ROIDT	Marked vascular ectasia and thrombosis consistent with hemorrhoids.	GI
RXG	Reactive gastropathy	GI
SACC	Severely active chronic colitis	GI
SAD	Serrated adenoma	GI
SAGC	Severely active granulomatous colitis.	GI
SEAC	Severely active colitis	GI
SEFA	Subepithelial fibrosis is absent.	GI
SEFC	Subepithelial fibrosis cannot be assessed.	GI
SEFP	Subepithelial fibrosis is present.	GI
SFIB0	Trichrome stain shows no fibrosis (modified Brunt stage 0 of 4).	GI
SFIB1a	Trichrome stain shows mild sinusoidal fibrosis in zone 3 (modified Brunt stage 1a of 4).	GI
SFIB1b	Trichrome stain shows moderate sinusoidal fibrosis in zone 3 (modified Brunt stage 1b of 4).	GI
SFIB1c	Trichrome stain shows sinusoidal fibrosis in zone 1 (modified Brunt stage 1c of 4).	GI
SFIB2	Trichrome stain shows sinusoidal fibrosis in both zones 3 and 1 (modified Brunt stage 2 of 4).	GI
SFIB3	Trichrome stain shows bridging fibrosis (modified Brunt stage 3 of 4).	GI
SFIB4	Trichrome stain shows cirrhosis (modified Brunt stage 4 of 4).	GI
SGBFA	Segment of gastric body/fundus with increased submucosa adipose tissue.	GI
SGFIM	Squamoglandular junctional mucosa with focal intestinal metaplasia. Note: Could be Barrett's. No dysplasia.	GI
SGIM	Squamoglandular junctional mucosa with intestinal metaplasia. Note: Could be Barrett's. No dysplasia.	GI
SGJM	Squamoglandular junctional mucosa	GI
SGM	Specialized glandular mucosa	GI
SGR1	The biopsy shows grade 1 of 3 steatosis (5-33%)	GI
SGR2	The biopsy shows grade 2 of 3 steatosis (33-66%)	GI
SGR3	The biopsy shows grade 3 of 3 steatosis (> 66%)	GI
SIM	Small intestinal mucosa	GI
SINV	Small intestinal mucosa with normal villous architecture	GI
SLEA	Superficial layering of eosinophils is absent.	GI
SLEP	Superficial layering of eosinophils is present.	GI
SRUS	Ulcerated polypoid mucosa with features of mucosal prolapse (see note). Note: the findings are consistent with the polypoid phase of solitary rectal ulcer syndrome.	GI
SSAP	Sessile serrated polyp/adenoma.	GI
SSAPN	Note: This type of polyp may be a precursor of microsatellite unstable colorectal carcinomas.	GI
STEA	Steatosis with xxx features of steatohepatitis and xxx	GI
TAD	Tubular adenoma	GI
TINAD	There is no evidence of adenoma	GI
TINEC	There is no evidence of colitis.	GI
TINIM	There is no evidence of intestinal metaplasia.	GI
TINIMD	There is no evidence of intestinal metaplasia or dysplasia.	GI
TVA	Tubulovillous adenoma	GI
VAD	Villous adenoma	GI
BPH	Benign prostatic hyperplasia	GU
BPT	Benign prostate tissue	GU
CCRCC	Clear cell renal cell carcinoma	GU
CPACA	Prostatic Adenocarcinoma Gleason score 3 + 3 = 6/10 (Grade Group 1) Number of Cores Involved: Percentage and length of cores involved: Perineural invasion is:	GU
CRCC	Chromophobe renal cell carcinoma	GU
NEGMUSC	Muscularis propria is present and not involved by tumor.	GU
NOMUSC	No muscularis propria is present.	GU
PACA	Prostatic adenocarcinoma	GU
PRCC	Papillary renal cell carcinoma	GU
PUCH	Papillary urothelial carcinoma, high grade (WHO grade 3)	GU
PUCHLP	Papillary urothelial carcinoma (WHO grade 3), invasive of the lamina propria (pT1)	GU
PUCHMP	Papillary urothelial carcinoma (WHO grade 3), invasive of the muscularis propria (pT2)	GU
PUCHNI	Papillary urothelial carcinoma, non-invasive (pTa)	GU
PUCL	Papillary urothelial carcinoma, low grade (WHO Grade 2)	GU
PUCLLP	Papillary urothelial carcinoma, low grade (WHO grade 2), invasive of the lamina propria (pT1)	GU
PUCLMP	Papillary urothelial carcinoma, low grade (WHO grade 2), invasive of the muscularis propria (T2)	GU
PUNLMP	Papillary urothelial neoplasm of low malignant potential (WHO Grade 1)	GU
TCC	Transitional cell carcinoma	GU
TCCIS	Transitional cell carcinoma in situ (pTis); no invasive carcinoma identified.	GU
TCCLP	Transitional cell carcinoma, grade 3 of 3, invasive of the lamina propria (pT1).	GU
TCCMP	Transitional cell carcinoma, grade 3 of 3, invasive of the muscularis propria (pT2).	GU
UCIS	Urothelial carcinoma in situ (pTis)	GU
YESMUSC	Muscularis propria is present.	GU
AE	ATROPHIC ENDOMETRIUM	GYN
AGLAND	Fragments of aglandular functionalis suggestive of underlying submucosal leiomyoma.	GYN
AMYOS	adenomyosis	GYN
ANOV	DISORDERED ENDOMETRIUM CONSISTENT WITH ANOVULATORY CYCLE.	GYN
ASM	ATYPICAL SQUAMOUS METAPLASIA	GYN
BC	BARTHOLIN'S CYST	GYN
BCA	BARTHOLIN'S CYST ABSCESS	GYN
BLH	BASAL LAYER HYPERPIGMENTATION.	GYN
BSM	BENIGN SQUAMOUS MUCOSA	GYN
CC	CHRONIC CERVICITIS	GYN
CEND	CHRONIC ENDOMETRITIS	GYN
CF	CYSTIC FOLLICLES	GYN
CH	CYSTIC HYPERPLASIA	GYN
CIC	CORTICAL (MESOTHELIAL) INCLUSION CYST(S)	GYN
CONDY	CONDYLOMA ACUMINATUM	GYN
CONDYS	CONDYLOMATA ACUMINATA	GYN
CONH	consistent with a high grade squamous intraepithelial lesion.	GYN
CONL	consistent with a low grade squamous intraepithelial lesion.	GYN
DRUG	ALTERED ENDOMETRIUM WITH GLANDULAR AND STROMAL CHANGES CONSISTENT WITH EXOGENOUS HORMONE THERAPY EFFECT.	GYN
EC	ENDOCERVIX	GYN
ECP	ENDOCERVICAL POLYP	GYN
EEG	EXTENDING INTO ENDOCERVICAL GLANDS	GYN
EHYP	ENDOMETRIAL HYPERPLASIA WITH # ARCHITECTURAL AND # CYTOLOGICAL ATYPIA.	GYN
EIN	Endometrial intraepithelial neoplasia (atypical hyperplasia)	GYN
EMCA	ENDOMETRIAL CARCINOMA, ENDOMETRIOID TYPE, GRADE	GYN
EMOS	ENDOMETRIOSIS	GYN
EMP	ENDOMETRIAL POLYP	GYN
ENDO	ENDOMETRIUM	GYN
ETP	CHORIONIC VILLI AND HEMORRHAGE CONSISTENT WITH ECTOPIC TUBAL PREGNANCY	GYN
FASE	Fragments of atrophic surface endometrium.	GYN
FC	FOLLICULAR CERVICITIS	GYN
FCON	FLAT CONDYLOMA	GYN
FEE	FRAGMENTS OF ENDOCERVICAL EPITHELIUM	GYN
FEM	FRAGMENT OF ENDOCERVICAL MUCOSA	GYN
FGSE	FRAGMENTS OF GLYCOGENATED SQUAMOUS EPITHELIUM	GYN
FISE	Fragments of inactive surface endometrium.	GYN
FOBE	Fragments of benign endocervix.	GYN
FREE	Margins are uninvolved by the lesion.	GYN
FSM	FRAGMENT OF SMOOTH MUSCLE	GYN
FSML	FRAGMENT OF SMOOTH MUSCLE CONSISTENT WITH LEIOMYOMA	GYN
FSSM	FRAGMENTS OF SMOOTH MUSCLE	GYN
FUEE	FRAGMENTS OF UNREMARKABLE ENDOCERVICAL EPITHELIUM	GYN
FUEEM	FRAGMENTS OF UNREMARKABLE ENDOCERVICAL MUCOSA AND EPITHELIUM.	GYN
FUEES	FRAGMENTS OF UNREMARKABLE ENDOCERVICAL AND SQUAMOUS EPITHELIUM.	GYN
GCROWD	These changes are not sufficient for a diagnosis of endometrial intraepithelial neoplasia (EIN/atypical hyperplasia); however, focal gland crowding is followed by EIN on a subsequent sample in about 20% of cases. Followup sampling is advised in 4-6 months to exclude EIN, or earlier if there are clinical concerns. See: Huang EC, Mutter GL, Crum CP, Nucci MR. Clinical outcome in diagnostically ambiguous foci of 'gland	GYN
GLINV	with endocervical gland involvement	GYN
GT	GRANULATION TISSUE	GYN
HG	HYPERGRANULOSIS	GYN
HGSC	high grade serous carcinoma	GYN
HPV	HUMAN PAPILLOMAVIRUS	GYN
HSE	HYPERSECRETORY ENDOMETRIUM	GYN
IE	INACTIVE ENDOMETRIUM	GYN
ISM	IMMATURE SQUAMOUS METAPLASIA	GYN
KOILO	KOILOCYTOSIS	GYN
LEIO	leiomyoma	GYN
LEIOS	leiomyomata	GYN
LUS	LOWER UTERINE SEGMENT	GYN
ME	MENSTRUAL ENDOMETRIUM	GYN
METPAP	Metastatic high grade serous carcinoma	GYN
MGH	MICROGLANDULAR HYPERPLASIA	GYN
MIX	ALTERED ENDOMETRIUM WITH A MIXED PROLIFERATIVE AND SECRETORY	GYN
MORULES	Squamous morular metaplasia, either isolated or associated with mild gland crowding, carries a mildly increased risk of an endometrial cancer outcome (approximately 5%) and may resolve spontaneously. However, followup with a repeat endometrial sample in approximately 3-6 months is advised to exclude persistence, as clinically appropriate.	GYN
MPE	MENSTRUAL PATTERN ENDOMETRIUM	GYN
MSE	MATURE SQUAMOUS EPITHELIUM	GYN
MSM	MATURE SQUAMOUS METAPLASIA	GYN
NFT	negative for tumor.	GYN
OME	Ovulatory menstrual endometrium	GYN
PBS	PREVIOUS BIOPSY SITE	GYN
PE	PROLIFERATIVE ENDOMETRIUM	GYN
PEC	PROLIFERATIVE ENDOMETRIUM WITH FOCAL CYSTIC DILATATION	GYN
PGT	POLYPOID GRANULATION TISSUE	GYN
PILL	Endometrial gland and stromal changes consistent with oral contraceptive effect.	GYN
POC	CHORIONIC VILLI AND DECIDUA CONSISTENT WITH INTRAUTERINE PREGNANCY	GYN
PPE	PROLIFERATIVE PATTERN ENDOMETRIUM	GYN
PTC	PARATUBAL CYSTS	GYN
REED	Although not entirely specific, the distinctive morphology of atypical smooth muscle cells in combination of cleared chromatin, prominent nucleoli and eosinophilic cytoplasmic inclusions, raises the possibility of hereditary leiomyomatosis and renal cell cancer (HLRCC) syndrome (also known as reed syndrome). Consideration of medical genetics consultation, testing for germline fumarate hydratase (FH) gene mutation, and screening for renal cell carcinoma could be considered if clinically feasible. In this context, review of family history and dermatologic examination for cutaneous leiomyomata are advised (ref: Sanz-Ortega, J. et al., Am J Surg Pathol 2013; 27:74-80).	GYN
RSC	REACTIVE SQUAMOUS CHANGES	GYN
RSM	REACTIVE SQUAMOUS METAPLASIA	GYN
RX	REACTIVE	GYN
SCAE	SCANT ATROPHIC ENDOMETRIUM.	GYN
SCIS	SQUAMOUS CELL CARCINOMA IN SITU	GYN
SD	SQUAMOUS DYSPLASIA	GYN
SE	SECRETORY ENDOMETRIUM	GYN
SED	SECRETORY ENDOMETRIUM, DAY	GYN
SEDEL	Secretory endometrium, delayed ovulatory type. Comment: the presence of scattered cysts and/or fibrin thrombi suggests a protracted estrogenic (“follicular”) phase prior to ovulation.	GYN
SM	SQUAMOUS METAPLASIA	GYN
SONE	Fragments of dysplastic squamous epithelium	GYN
STIC	serous tubal intraepithelial carcinoma	GYN
TM	TUBAL METAPLASIA	GYN
TOAD	TUBO-OVARIAN ADHESIONS	GYN
TUBE	UNREMARKABLE PORTION OF OVIDUCT; COMPLETE CROSS SECTION DEMONSTRATED.	GYN
TWEENER	This lesion has features that are intermediate to those of LSIL and HSIL (CIN 2). Potential management options include clinical follow-up versus excision as clinically appropriate.	GYN
TZ	TRANSFORMATION ZONE	GYN
VU	VULVAR ULCER	GYN
WPE	WEAKLY PROLIFERATIVE ENDOMETRIUM	GYN
ABL	Atypical Burkitt's lymphoma	HP
AEL	Acute erythroid leukemia	HP
AFH	Angiofollicular hyperplasia (Castleman's disease)	HP
AITL	Angioimmunoblastic T-cell lymphoma	HP
ALCL	Anaplastic large cell lymphoma	HP
ALL	Acute lymphblastic leukemia	HP
AML	Acute myeloid leukemia	HP
AMML	Acute myelomonocytic leukemia	HP
AMOL	Acute monoblastic leukemia	HP
APML	Acute promyelocytic leukemia	HP
ATLL	Adult T Cell Lymphoma/Leukemia	HP
BCL	B-cell lymphoma	HP
BCLU	B-cell lymphoma, unclassifiable, with features intermediate between diffuse large B-cell lymphoma and Burkitt's lymphoma	HP
BL	Burkitt's lymphoma	HP
CAMD	Paraffin tissue/Touch preps/Fresh tissue/Frozen tissue from this case was submitted to the Center for Advanced Molecular Diagnostics at Brigham and Women's Hospital (XXXXXXXXXX). Results are as follows:	HP
CD	Castleman's disease	HP
CDHV	Castleman's disease, hyaline vascular variant	HP
CDPC	Castleman's disease, plasma cell variant	HP
CHL	Classical Hodgkin's lymphoma	HP
CLL	Chronic lymphocytic leukemia	HP
CML	Chronic myelogenous leukemia	HP
CMML	Chronic myelomonocytic leukemia	HP
DFNS	Diagnostic features of XXXXXXX are not seen.	HP
DINT	A concurrent peripheral blood smear has been reviewed for morphological correlation of these findings (see CBC/differential report of DATE with pathologist's interpretation).	HP
DLBCL	Diffuse large B-cell lymphoma	HP
EBER	Epstein-Barr virus encoded RNA (EBER)	HP
EBERNEG	In-situ hybridization reveals no staining with an oligonucleotide probe for EBV-encoded RNA (EBER).	HP
EBERPOS	In-situ hybridization with an oligonucleotide probe specific for EBV encoded RNA (EBER) reveals positive staining of	HP
EBV	Epstein-Barr virus	HP
EMZL	Extranodal marginal zone lymphoma of mucosa-associated lymphoid tissue	HP
ENKTL	Extranodal NK/T-cell lymphoma, nasal type	HP
FDAIP	This immunoperoxidase test was developed and its performance characteristics determined by the Pathology Department at the Massachusetts General Hospital. It has not been cleared or approved by the U.S. Food and Drug Administration (FDA). The FDA has determined that such clearance or approval is not necessary; this laboratory has established and verified the test's accuracy and precision.	HP
FDC	Follicular dendritic cells	HP
FL	Follicular lymphoma	HP
FL12	Follicular lymphoma, grade 1-2 of 3	HP
FL3A	Follicular lymphoma, grade 3A of 3	HP
FL3B	Follicular lymphoma, grade 3B of 3	HP
FLIFD	Selected markers were evaluated by immunohistochemistry as well as flow cytometry because their expression by flow cytometry was not reliably demonstrated in the cells of interest.	HP
FLIM	Selected markers were evaluated by immunohistochemistry as well as flow cytometry to assess their expression in the context of the tissue architecture.	HP
FLINT	A concurrent fluid cytospin slide from the Core Hematology Laboratory has been reviewed for morphological correlation of these findings (see fluid cell count/differential report of DATE with pathologist's interpretation).	HP
FLIS	Follicular lymphoma in situ	HP
FLISN	Follicular lymphoma in situ NOTE	HP
FLOS	According to the accompanying report, flow cytometry performed at the outside insitution revealed	HP
GIEM	Giemsa stain was examinated as part of the histologic evaluation of this case.	HP
GZL	B-cell lymphoma, unclassifiable, with features intermediate between diffuse large B-cell lymphoma and classical Hodgkin's lymphoma	HP
HCL	Hairy cell leukemia	HP
HOMTH	hypocellular marrow with maturing trilineage hematopoiesis	HP
HSTCL	Hepatosplenic T-cell lymphoma	HP
HYMTH	hypercellular marrow with maturing trilineage hematopoiesis	HP
IDDC	interdigitating dendritic cells	HP
IHCKL	Immunohistochemistry for kappa and lambda immunoglobulin light chains	HP
IHCOSH	Examination of immunostains submitted for review shows	HP
IHCP	Immunoperoxidase stains on paraffin sections reveal	HP
ISHEBER	In-situ hybridization for Epstein-Barr virus encoced RNA (EBER)	HP
ISHKL	In-situ hybridization for kappa and lambda immunoglobulin light chains	HP
IVBL	Intravascular large B-cell lymphoma	HP
KLIG	kappa and lambda immunoglobulin light chains	HP
LBL	Acute lymphoblastic lymphoma	HP
LDCHL	Lymphocyte-depleted classical Hodgkin's lymphoma	HP
LGL	large granular lymphocyte	HP
LGLL	large granular lymphocytic leukemia	HP
LNIG	Lymph node with increased IgG4+ plasma cells NOTE	HP
LNIG	(for RLH with increased IgG4+ plasma cells)	HP
LRCHL	Lymphocyte-rich classical Hodgkin's lymphoma	HP
LYG	Lymphomatoid granulomatosis	HP
LYPL	Lymphoplasmacytic lymphoma	HP
MALT	Mucosa-associated lymphoid tissue	HP
MBL	Monoclonal B-cell lymphocytosis	HP
MCCHL	Mixed cellularity classical Hodgkin's lymphoma	HP
MCL	Mantle cell lymphoma	HP
MDS	Myelodysplastic/myeloproliferative neoplasm	HP
MGUS	Monoclonal gammopathy of undetermined significance	HP
MHOM	Markedly hypocellular marrow	HP
MHYM	Markedly hypercellular marrow	HP
MPAL	Mixed phenotype acute leukemia	HP
MPN	Myeloproliferative neoplasma	HP
MTH	maturing trilineage hematopoiesis	HP
MZL	Marginal zone lymphoma	HP
NLPHL	Nodular lymphocyte predominant Hodgkin's lymphoma	HP
NMTH	Normocellular marrow with trilineage hematopoeisis	HP
NMZL	Nodal marginal zone lymphoma	HP
NSCHL	Nodular sclerosis classical Hodgkin's lymphoma	HP
PBL	Plasmablastic lymphoma	HP
PCDLBCL	Primary cutaneous diffuse large B-cell lymphoma, leg type	HP
PCFCL	Primary cutaneous follicle center lymphoma	HP
PCMZL	Primary cutaneous marginal zone lymphoma	HP
PCN	Plasma cell neoplasm	HP
PEL	Primary effusion lymphoma	HP
PLCM	Plasma cell myeloma	HP
PLL	Prolymphocytic leukemia	HP
PMBL	Primary mediastinal B-cell lymphoma	HP
PMF	Primary myelofibrosis	HP
PSRE	Review of the peripheral smear reveals	HP
PTCL	Peripheral T-cell lymphoma	HP
PTCLNOS	Peripheral T-cell lymphoma, not otherwise specified	HP
PTGC	Progressive transformation of germinal centers	HP
PTLD	Post-transplant lymphoproliferative disorder	HP
RA	Refractory anemia	HP
RAEB	Refractory anemia with excess blasts	HP
RARS	Refractory anemia with ring sideroblasts	HP
RCMD	Refractory cytopenia with multilineage dysplasia	HP
RET	No increase in reticulin	HP
RET1	1+ out of 3 fiber staining	HP
RET2	2+ out of 3 fiber staining	HP
RET3	3+ out of 3 fiber staining	HP
RFH	Reactive follicular hyperplasia	HP
RSAV	Reed-Sternberg cells and variants	HP
RSVAR	Reed-Sternberg cell variants	HP
RSVAR	Reed-Sternberg cells	HP
SDRP	Splenic diffuse red pulp small B-cell lymphoma	HP
SHML	Sinus histiocytosis with massive lymphadenopathy	HP
SLL	Small lymphocytic lymphoma	HP
SMZL	Splenic marginal zone lymphoma	HP
TCL	T-cell lymphoma	HP
TCRAB	T-cell receptor alpha/beta	HP
TCRGD	T-cell receptor gamma/delta	HP
TCRLBCL	T-cell/histiocyte-rich large B-cell lymphoma	HP
WHOP	Subclassification of this acute leukemia according to the WHO Classification is pending results of cytogenetics.	HP
WM	Waldenstrom's macroglobulinemia	HP
MGMTAD	Testing for methylation status of the MGMT promoter will be performed and reported subsequently.	NP
MKHI	The Ki67 labeling index in the present case is XX%. The presence of a Ki67 labeling index greater than 3% has been correlated with the recurrence of meningiomas, and the elevated proliferation index present in this case may indicate more aggressive biologic potential of the tumor. See note. Note: This immunoperoxidase test was developed and its performance characteristics determined by the Pathology Department at the Massachusetts General Hospital. It has not been cleared or approved by the U.S. Food and Drug Administration (FDA). The FDA has determined that such clearance or approval is not necessary; this laboratory has established and verified the test's accuracy and precision.	NP
MKLO	The Ki67 labeling index in the present case is low, at XX%. The presence of a Ki67 labeling index greater than 3% has been correlated with the recurrence of meningiomas. See note. Note: This immunoperoxidase test was developed and its performance characteristics determined by the Pathology Department at the Massachusetts General Hospital. It has not been cleared or approved by the U.S. Food and Drug Administration (FDA). The FDA has determined that such clearance or approval is not necessary; this laboratory has established and verified the test's accuracy and precision.	NP
ABRUPT	Note: The diagnosis of acute abruption is best made clinically and by immediate examination of the freshly delivered placenta. Histologic findings are rare and non-specific and the absence of them do not negate the diagnosis. Clinical correlation is suggested.	OB
ACHA	ACUTE CHORIOAMNIONITIS (MATERNAL STAGE X; GRADE X)	OB
ACHAF	ACUTE CHORIOAMNIONITIS (MATERNAL STAGE X; GRADE X) WITH FETAL VASCULAR INVOLVEMENT (FETAL STAGE X; GRADE X)	OB
ACVM	ACCELERATED VILLOUS MATURATION (SMALL VILLI WITH LARGE SYNCYTIAL KNOTS AND VILLOUS SCLEROSIS). SEE NOTE. NOTE: These findings are associated with chronic uteroplacental insufficiency.	OB
AGA	APPROPRIATE FOR GESTATIONAL AGE	OB
AVE	ACUTE VILLOUS EDEMA	OB
CHOR	CHORANGIOSIS	OB
CLINICO	CLINICAL CORRELATION IS SUGGESTED.	OB
CM	COMPLETE HYDATIFORM MOLE	OB
CYTO	COMMENT: Tissue was sent for cytogenetics and the results will be reported seperately.	OB
DDTP	DIAMNIONIC, DICHORIONIC TWIN PLACENTA	OB
DEC	DECIDUA	OB
DMPT	DIAMNIONIC, MONOCHORIONIC TWIN PLACENTA. SEE NOTE.	OB
DV	DECIDUAL VASCULOPATHY	OB
FRAG	NOTE: Fragmentation precludes optimal evaluation for structural malformations and determination of gender.	OB
FRIP	FRAGMENTS OF IMMATURE PLACENTA	OB
FVM	FETAL VASCULAR MALPERFUSION	OB
FVMN	FETAL VASCULAR MALPERFUSION (SEE NOTE). Note: The differential diagnosis includes anatomical obstruction (e.g. true knot, velamentous vessels), inflammatory (chronic villitis, chorionic plate inflammation), toxic (meconium myonecrosis, infant of an IDDM mother), and hereditary thrombophilia. In this case we favor XXX.	OB
GA	GESTATIONAL AGE	OB
IMPL	PLACENTAL IMPLANTATION SITE	OB
IP	IMMATURE PLACENTA	OB
IUFD	INTRAUTERINE FETAL DEMISE	OB
IUGR	INTRAUTERINE GROWTH RESTRICTION	OB
IUP	INTRAUTERINE PREGNANCY	OB
IVT	INTERVILLOUS THROMBUS	OB
MEC	PIGMENT LADEN MACROPHAGES IN AMNION CONSISTENT WITH MECONIUM	OB
MMTP	MONOAMNIONIC, MONOCHORIONIC TWIN PLACENTA. SEE NOTE. NOTE: Monochorionic placentas are monozygous.	OB
MP	MATURE PLACENTA	OB
NOVIL	NO VILLI OR TROPHOBLAST PRESENT, ENTIRE SPECIMEN EXAMINED. SEE NOTE. NOTE: Pregnancy has not been confirmed and ectopic pregnancy cannot be excluded. Clinical correlation is advised. Dr. XXXX notified by Dr. YYYY on DATE at TIME.	OB
NV	NECROTIC IMMATURE CHORIONIC VILLI	OB
PLIN	PLACENTAL INFARCT	OB
PM	PARTIAL HYDATIDIFORM MOLE	OB
SIP	SLIGHTLY IMMATURE PLACENTA	OB
SUA	SINGLE UMBILICAL ARTERY. SEE NOTE. NOTE: Approximately 2% of cases of single umbilical artery are associated with renal anomalies including pelvic kidney, unilateral renal agenesis, or horseshoe kidney. If it was not done antenatally, a renal evaluation should be considered.	OB
THEFOL	THE FOLLOWING ORGANS/TISSUES ARE PRESENT AND ARE APPROPRIATE FOR GESTATIONAL AGE:	OB
UC	UMBILICAL CORD	OB
VUE	VILLITIS OF UNKNOWN ETIOLOGY	OB
ZYGO	NOTE: Zygosity cannot be determined by placental examination	OB